Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

 Sunitinib

Sunitinib malate is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. 

Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. SUTENT (sunitinib malate) capsules are supplied as printed hard shell capsules containing sunitinib malate equivalent to 12.5 mg, 25 mg or 50 mg of sunitinib together with mannitol, croscarmellose sodium, povidone (K-25) and magnesium stearate as inactive  ngredients. The orange gelatin capsule shells contain titanium dioxide, and red iron oxide. The caramel gelatin capsule shells also contain yellow iron oxide and black iron oxide. The printing ink contains shellac, propylene glycol, sodium hydroxide, povidone and titanium dioxide.

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib has become a standard of care for both of these cancers, and is currently being studied for the treatment of many others.

According to http://en.wikipedia.org/wiki/Sunitinib, Sunitinib is a standard of care in the first-line treatment of metastatic RCC, other therapeutic options in this setting are sorafenib (Nexavar), temsirolimus (Torisel) and interleukin-2 (Proleukin). RCC is generally resistant to chemotherapy or radiation. Prior to RTKs, metastatic disease could only be treated with the cytokines interferon alpha (IFNα) or Interleukin 2 (IL-2). However, these agents demonstrated low rates of efficacy (5%-20%). In two separate Phase II studies, sunitinib demonstrated consistent response rates of approximately 40% in patients who had already failed cytokine therapy. Although these were Phase II studies, these results were impressive enough for the FDA to approve sunitinib for first-line use even before Phase III data were available. The results of the Phase III study, published in the New England Journal of Medicine in 2007, proved that sunitinib offers superior efficacy compared with IFNα. Progression-free survival (primary endpoint) was more than doubled: 11 months for sunitinib compared with 5 months for IFNα (P<.000001). The benefit for sunitinib was significant across all major patient subgroups, including those with a poor prognosis at baseline. Secondary endpoints also favored sunitinib. 28% of sunitinib patients had significant tumor shrinkage (objective response) compared with only 5% of patients who received IFNα (P<.001). Although overall survival data are not yet mature, there is a clear trend toward improved survival with sunitinib. Patients receiving sunitinib also reported a significantly better quality of life than those treated with IFNα (P<.001).

  1: Lee JH, Chang SG, Jeon SH, Min GE, Yoo KH. Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea. Korean J Urol. 2010 Jun;51(6):379-85. Epub 2010 Jun 21. PubMed PMID: 20577603.

2: Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A. Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience. Br J Cancer. 2010 Jun 22. [Epub ahead of print] PubMed PMID: 20571495.

3: Pal SK, Figlin RA, Reckamp K. Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape. Mol Cancer Ther. 2010 Jun 22. [Epub ahead of print] PubMed PMID: 20571071.

4: Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2010 May 28. [Epub ahead of print] PubMed PMID: 20570050.

5: Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE, Wirth LJ. Neoadjuvant Treatment of Unresectable Medullary Thyroid Cancer With Sunitinib. J Clin Oncol. 2010 Jun 21. [Epub ahead of print] PubMed PMID: 20567012.

6: Chabot I, Rocchi A. How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma. Value Health. 2010 Jun 7. [Epub ahead of print] PubMed PMID: 20561332.

7: Gangjee A, Zhao Y, Raghavan S, Ihnat MA, Disch BC. Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem. 2010 May 25. [Epub ahead of print] PubMed PMID: 20558072.

8: Gkountouvas A, Kostoglou-Athanassiou I, Veniou E, Repousis P, Ziras N, Kaldrimidis P. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer. Thyroid. 2010 Jun;20(6):597-600. PubMed PMID: 20553195.

9: Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatellier G, Frija G, Cuenod CA. Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT. Radiology. 2010 Jun 15. [Epub ahead of print] PubMed PMID: 20551183.

10: Demirci U, Coskun U, Erdem O, Ozturk B, Yilmaz IB, Benekli M, Buyukberber S. Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient. J Oncol Pharm Pract. 2010 Jun 15. [Epub ahead of print] PubMed PMID: 20551113.

11: Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; for the RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Jun 14. [Epub ahead of print] PubMed PMID: 20549832.

12: Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde AR, Dal Cin P, Choueiri TK. Sunitinib-Induced Pseudoprogression After Whole-Brain Radiotherapy for Metastatic Renal Cell Carcinoma. J Clin Oncol. 2010 Jun 14. [Epub ahead of print] PubMed PMID: 20547999.

13: Girardi F, Franceschi E, Brandes AA. Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies. Oncologist. 2010 Jun 14. [Epub ahead of print] PubMed PMID: 20547589.

14: Constantine LA, Huggett DB. A comparison of the chronic effects of human pharmaceuticals on two cladocerans, Daphniamagna and Ceriodaphniadubia. Chemosphere. 2010 Jun 12. [Epub ahead of print] PubMed PMID: 20547406.

15: Kutach AK, Villaseñor AG, Lam D, Belunis C, Janson C, Lok S, Hong LN, Liu CM, Deval J, Novak TJ, Barnett JW, Chu W, Shaw D, Kuglstatter A. Crystal Structures of IL-2-inducible T cell Kinase Complexed with Inhibitors: Insights into Rational Drug Design and Activity Regulation. Chem Biol Drug Des. 2010 Jun 9. [Epub ahead of print] PubMed PMID: 20545945.

16: Oya M. [mTOR inhibitors]. Nippon Rinsho. 2010 Jun;68(6):1067-71. Japanese. PubMed PMID: 20535957.

17: Bayraktar UD, Bayraktar S, Rocha-Lima CM. Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol. 2010 Jun 14;16(22):2726-34. PubMed PMID: 20533592; PubMed Central PMCID: PMC2883128.

18: Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics. 2010 May 25;4:91-101. PubMed PMID: 20531964; PubMed Central PMCID: PMC2880340.

19: Bäuerle T, Merz M, Komljenovic D, Zwick S, Semmler W. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res. 2010 Jun 15;16(12):3215-25. Epub 2010 Jun 8. PubMed PMID: 20530698.

20: Abouantoun TJ, Castellino RC, Macdonald TJ. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol. 2010 Jun 4. [Epub ahead of print] PubMed PMID: 20524040.

21: Coriat R, Ropert S, Mir O, Billemont B, Chaussade S, Massault PP, Blanchet B, Vignaux O, Goldwasser F. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs. 2010 Jun 5. [Epub ahead of print] PubMed PMID: 20524036.

22: Bozas G, Roy A, Ramasamy V, Maraveyas A. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie. 2010;33(6):321-3. Epub 2010 May 11. PubMed PMID: 20523097.

23: von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib. Leukemia. 2010 Jun 3. [Epub ahead of print] PubMed PMID: 20520641.

24: Hanzer M, Nebl A, Spendel S, Pilhatsch A, Urban C, Benesch M. Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh. Klin Padiatr. 2010 May;222(3):184-6. Epub 2010 May 31. PubMed PMID: 20514624.

25: Sjölund K, Andersson A, Nilsson E, Nilsson O, Ahlman H, Nilsson B. Downsizing Treatment with Tyrosine Kinase Inhibitors in Patients with Advanced Gastrointestinal Stromal Tumors Improved Resectability. World J Surg. 2010 May 29. [Epub ahead of print] PubMed PMID: 20512492.

26: van Erp NP, Baker SD, Zandvliet AS, Ploeger BA, den Hollander M, Chen Z, den Hartigh J, König-Quartel JM, Guchelaar HJ, Gelderblom H. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol. 2010 May 29. [Epub ahead of print] PubMed PMID: 20512335.

27: Dai Y. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opin Ther Pat. 2010 Jul;20(7):885-97. PubMed PMID: 20509775.

28: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. PubMed PMID: 20508873.

29: Schöffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, Hollaender N, Jappe A, Demetri GD. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010 May 27. [Epub ahead of print] PubMed PMID: 20507881.

30: Michalaki V, Arkadopoulos N, Kondi-Pafiti A, Gennatas C. Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment. World J Surg Oncol. 2010 May 28;8:45. PubMed PMID: 20507643; PubMed Central PMCID: PMC2890518.

31: Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A. Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice. Cancer Invest. 2010 May 26. [Epub ahead of print] PubMed PMID: 20504222.

32: Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One. 2010 May 19;5(5):e10715. PubMed PMID: 20502715; PubMed Central PMCID: PMC2873294.

33: Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010 Jun;9(6):1525-35. Epub 2010 May 25. PubMed PMID: 20501804.

34: Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJ. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 May 23. [Epub ahead of print] PubMed PMID: 20497961.

35: Deshpande HA, Gettinger SN, Sosa JA. Targeted therapy for thyroid cancer: An updated review of investigational agents. Curr Opin Investig Drugs. 2010 Jun;11(6):661-8. PubMed PMID: 20496261.

36: Laderoute KR, Calaoagan JM, Madrid PB, Klon AE, Ehrlich PJ. SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). Cancer Biol Ther. 2010 Jul 26;10(1). [Epub ahead of print] PubMed PMID: 20495370.

37: Ayllon J, Pignot G. [Anti-angiogenic therapies and hemorrhagic risk]. Prog Urol. 2010 Mar;20 Suppl 1:S20-2. French. PubMed PMID: 20493438.

38: Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010 Jun;194(6):1470-8. PubMed PMID: 20489085.

39: Miller K, Bergmann L, Albers P, Gschwend J, Jäger E, Keilholz U. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol. 2010 May;41(3):193-6. Epub 2010 May 18. German. PubMed PMID: 20486036.

40: Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. Br J Cancer. 2010 Jun 8;102(12):1699-706. Epub 2010 May 18. PubMed PMID: 20485286.

41: Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010 Jul;22(4):351-5. PubMed PMID: 20485168.

42: Levashova Z, Backer M, Hamby CV, Pizzonia J, Backer JM, Blankenberg FG. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med. 2010 Jun;51(6):959-66. Epub 2010 May 19. PubMed PMID: 20484434.

43: Tardieu M, Dômont J, Cioffi A, Bonvalot S, Le Cesne A. [Focus on GIST management]. Bull Cancer. 2010 Jun 1;97(6):723-31. French. PubMed PMID: 20483709.

44: Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, Gutzmer R. The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges. 2010 May 6. [Epub ahead of print] PubMed PMID: 20482685.

45: Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr Opin Oncol. 2010 Jul;22(4):381-6. PubMed PMID: 20473165.

46: Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol. 2010 May 13. [Epub ahead of print] PubMed PMID: 20471374.

47: Fuereder T, Jaeger-Lansky A, Hoeflmayer D, Preusser M, Strommer S, Cejka D, Koehrer S, Crevenna R, Wacheck V. mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett. 2010 May 12. [Epub ahead of print] PubMed PMID: 20471160.

48: Bukowski RM. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2010 May;10(5):635-45. PubMed PMID: 20469994.

49: Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4. PubMed PMID: 20457867.

50: Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs. 2010 May 15. [Epub ahead of print] PubMed PMID: 20467883.

51: Elice F, Rodeghiero F. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res. 2010 Apr;125 Suppl 2:S55-7. PubMed PMID: 20434006.

52: Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2010 May 12. [Epub ahead of print] PubMed PMID: 20461441.

53: Grünwald V, Kalanovic D, Merseburger AS. Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World J Urol. 2010 Jun;28(3):343-51. Epub 2010 May 11. PubMed PMID: 20458483.

54: Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010 Jun;7(6):327-38. Epub 2010 May 11. PubMed PMID: 20458330.

55: Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H. The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction. Jpn J Clin Oncol. 2010 May 10. [Epub ahead of print] PubMed PMID: 20457723.

56: Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010 May;9(5):1286-97. PubMed PMID: 20457621.

57: Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto O, Pastorelli D. An update on targeted therapy in metastatic renal cell carcinoma. Urol Oncol. 2010 Apr 22. [Epub ahead of print] PubMed PMID: 20456985.

58: Schmidinger M, Zielinski CC. Defining risk status in the first-line treatment of metastatic renal cell carcinoma. J Cancer Res Clin Oncol. 2010 Jul;136(7):961-8. Epub 2010 May 8. Review. PubMed PMID: 20454802.

59: Rini BI, Shah SN. Editorial comment. Urology. 2010 May;75(5):1114-5; author reply 1115. PubMed PMID: 20451727.

60: Vaishampayan U. Editorial comment. Urology. 2010 May;75(5):1114; author reply 1115. PubMed PMID: 20451726.

61: Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2010 May 5. [Epub ahead of print] PubMed PMID: 20451414.

62: Li XS, Song Y, Gong K, Zhang Q, Yu W, Song G, Zhao Z, Zhang Z, Wang G, Zhou LQ, He ZS, Jin J. [Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience]. Zhonghua Wai Ke Za Zhi. 2010 Mar 1;48(5):375-7. Chinese. PubMed PMID: 20450612.

63: Haouala A, Rumpold H, Untergasser G, Buclin T, Ris HB, Widmer N, Decosterd LA. siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. Drug Metab Lett. 2010 Apr 1;4(2):114-119. [Epub ahead of print] PubMed PMID: 20446917.

64: Dalhaug A, Haukland E, Nieder C. Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report). World J Surg Oncol. 2010 May 5;8:36. PubMed PMID: 20441600; PubMed Central PMCID: PMC2873341.

65: Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. Epub 2010 May 3. PubMed PMID: 20439632.

66: Zacchia M, Vilasi A, Capasso A, Morelli F, De Vita F, Capasso G. Genomic and proteomic approaches to renal cell carcinoma. J Nephrol. 2010 Apr 13. pii: ABE18130-25D6-4DA6-A346-2337576A9604. [Epub ahead of print] PubMed PMID: 20437403.

67: Norum J, Nieder C, Kondo M. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J Chemother. 2010 Apr;22(2):75-82. PubMed PMID: 20435564.

68: Goemans BF, Zwaan CM, Cloos J, de Lange D, Loonen AH, Reinhardt D, Hählen K, Gibson BE, Creutzig U, Kaspers GJ. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leuk Res. 2010 Apr 30. [Epub ahead of print] PubMed PMID: 20435347.

69: Antoniu SA, Kolb MR. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs. 2010 May;13(5):332-45. PubMed PMID: 20432191.

70: Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010;15(5):436-46. Epub 2010 Apr 28. PubMed PMID: 20427383.

71: Narayanan S, Callis-Duffin K, Batten J, Agarwal N. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci. 2010 Jun;339(6):580-1. PubMed PMID: 20421784.

72: Pouessel D, Patard JJ, Culine S. [Advanced renal carcinomas with special situations. How to treat them?]. Bull Cancer. 2010;97:83-90. French. PubMed PMID: 20418207.

73: Fléchon A, Boyle H, Négrier S. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]. Bull Cancer. 2010;97:73-82. French. PubMed PMID: 20418206.

74: Gross-Goupil M, Escudier B. [Targeted therapies: sequential and combined treatments]. Bull Cancer. 2010;97:65-71. French. PubMed PMID: 20418205.

75: Barrascout E, Medioni J, Scotte F, Ayllon J, Mejean A, Cuenod CA, Tartour E, Elaidi R, Oudard S. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. Bull Cancer. 2010;97:29-43. Review. French. PubMed PMID: 20418202.

76: Albouy B, Gross Goupil M, Escudier B, Massard C. [Renal cell carcinoma management and therapies in 2010]. Bull Cancer. 2010;97:17-28. French. PubMed PMID: 20418201.

77: Rossi A, Maione P, Sacco PC, Ambrosio R, Falanga M, Gridelli C. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. Curr Drug Targets. 2010 Jul;11(7):865-8784. PubMed PMID: 20412044.

78: Giehl M, Leitner A, Haferlach C, Duesberg P, Hofmann WK, Hofheinz R, Seifarth W, Hochhaus A, Fabarius A. Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. Eur J Haematol. 2010 Apr 16. [Epub ahead of print] PubMed PMID: 20408871.

79: LaPlant KD, Louzon PD. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann Pharmacother. 2010 Jun;44(6):1054-60. Epub 2010 Apr 20. PubMed PMID: 20407031.

80: Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010 May 1;70(9):3526-36. Epub 2010 Apr 20. Erratum in: Cancer Res. 2010 Jun 15;70(12):5196. PubMed PMID: 20406969.

81: Price J, Shaarbaf R, Wood L. Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma. Curr Oncol. 2010 Apr;17(2):30-3. PubMed PMID: 20404975; PubMed Central PMCID: PMC2854633.

82: Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control. 2010 Apr;17(1):120-9. PubMed PMID: 20404795.

83: Sánchez Zalabardo D, Millán Serrano JA, De Pablo Cárdenas A, Cuesta Alcalá JA. [Treatment of locally advanced renal tumors]. Actas Urol Esp. 2010 Feb;34(2):134-41. Spanish. PubMed PMID: 20403277.

84: Koch FP, Walter C, Hansen T, Jäger E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg. 2010 Apr 18. [Epub ahead of print] PubMed PMID: 20401503.

85: Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010 Apr 16. [Epub ahead of print] PubMed PMID: 20399520.

86: Tan TH, Pranavan G, Haxhimolla HZ, Yip D. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia Pac J Clin Oncol. 2010 Mar;6(1):5-18. PubMed PMID: 20398033.

87: Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, Diblasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010 Apr 15. [Epub ahead of print] PubMed PMID: 20394613.

88: Devarajan P. The promise of biomarkers for personalized renal cancer care. Kidney Int. 2010 May;77(9):755-7. PubMed PMID: 20393489.

89: Nieder C, Dalhaug A. A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis. Anticancer Res. 2010 Mar;30(3):977-9. PubMed PMID: 20393023.

90: Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95. Epub 2010 Apr 14. PubMed PMID: 20392874.

91: Reichardt P. Optimal use of targeted agents for advanced gastrointestinal stromal tumours. Oncology. 2010;78(2):130-40. Epub 2010 Apr 13. Review. PubMed PMID: 20389135.

92: Choueiri TK. Prognostic factors in patients treated with VEGF-targeted therapies. Clin Adv Hematol Oncol. 2010 Feb;8(2):92-3. PubMed PMID: 20386528.

93: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346.

94: Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Walraven M, Lind JS, Tibaldi C, Verheul HM, Peters GJ. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 May 1;878(15-16):1059-68. Epub 2010 Mar 15. PubMed PMID: 20382575.

95: Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sörgel F, Fuhr U, Jaehde U. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther. 2010 May;87(5):601-8. Epub 2010 Apr 7. PubMed PMID: 20376000.

96: Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010 Apr 4. [Epub ahead of print] PubMed PMID: 20371362.

97: Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol. 2010 May;7(5):277-88. Epub 2010 Apr 6. PubMed PMID: 20368728.

98: Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010 May 1;28(13):2131-6. Epub 2010 Apr 5. PubMed PMID: 20368560.

99: Cassier PA, Blay JY. Molecular response prediction in gastrointestinal stromal tumors. Target Oncol. 2010 Mar;5(1):29-37. Epub 2010 Apr 2. PubMed PMID: 20361266.

100: Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul;122(1):181-8. Epub 2010 Apr 2. PubMed PMID: 20361252.

101: Wood LS. New therapeutic strategies for renal cell carcinoma. Urol Nurs. 2010 Jan-Feb;30(1):40-53. PubMed PMID: 20359144.

102: Ping G, Hui-Min W, Wei-Min W, Bao-Hui H. Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population. Med Oncol. 2010 Mar 31. [Epub ahead of print] PubMed PMID: 20354819.

103: Schöffski P, Garfield DH, Hercbergs A, Wolter P. Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors. Br J Cancer. 2010 Apr 13;102(8):1309-10; author reply 1311. Epub 2010 Mar 30. PubMed PMID: 20354526; PubMed Central PMCID: PMC2856006.

104: Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010 May 1;28(13):2280-5. Epub 2010 Mar 29. Review. PubMed PMID: 20351323.

105: Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, Inui K. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol. 2010 Jun;21(6):1382-3. Epub 2010 Mar 26. PubMed PMID: 20348146.

106: Oosterwijk-Wakka JC, Kats-Ugurlu G, Leenders WP, Kiemeney LA, Old LJ, Mulders PF, Oosterwijk E. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2010 Mar 16. [Epub ahead of print] PubMed PMID: 20346054.

107: Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Mar 23. [Epub ahead of print] PubMed PMID: 20346042.

108: Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene. Cancer Sci. 2010 Feb 22. [Epub ahead of print] PubMed PMID: 20345483.

109: Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010 May;121(1):121-31. Epub 2010 Mar 26. PubMed PMID: 20339913; PubMed Central PMCID: PMC2855860.

110: van Rooijen E, Voest EE, Logister I, Bussmann J, Korving J, van Eeden FJ, Giles RH, Schulte-Merker S. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish. Dis Model Mech. 2010 May-Jun;3(5-6):343-53. Epub 2010 Mar 24. PubMed PMID: 20335444.

111: Purmonen T, Nuttunen P, Vuorinen R, Pyrhönen S, Kataja V, Kellokumpu-Lehtinen P. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncol. 2010 Mar 24. [Epub ahead of print] PubMed PMID: 20331406.

112: Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol. 2010 Mar 19. [Epub ahead of print] PubMed PMID: 20304669.

113: Dalton JE, Maroof A, Owens BM, Narang P, Johnson K, Brown N, Rosenquist L, Beattie L, Coles M, Kaye PM. Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest. 2010 Apr 1;120(4):1204-16. doi: 10.1172/JCI41281. Epub 2010 Mar 15. PubMed PMID: 20234089; PubMed Central PMCID: PMC2846033.

114: Fewkes NM, Krauss AC, Guimond M, Meadors JL, Dobre S, Mackall CL. Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation. Blood. 2010 May 20;115(20):4120-9. Epub 2010 Mar 15. PubMed PMID: 20231424; PubMed Central PMCID: PMC2875097.

115: Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Mar 2. [Epub ahead of print] PubMed PMID: 20230385.

116: Han KS, Jung DC, Choi HJ, Jeong MS, Cho KS, Joung JY, Seo HK, Lee KH, Chung J. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer. 2010 May 15;116(10):2332-42. PubMed PMID: 20225226.

117: Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY. Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. Urology. 2010 Mar 9. [Epub ahead of print] PubMed PMID: 20223508.

118: Tilson L, O'Leary A, Usher C, Barry M. Pharmacoeconomic evaluation in Ireland: a review of the process. Pharmacoeconomics. 2010 Apr 1;28(4):307-22. doi: 10.2165/11318790-000000000-00000. PubMed PMID: 20222754.

119: Pédeboscq S, Gravier D, Casadebaig F, Hou G, Gissot A, De Giorgi F, Ichas F, Cambar J, Pometan JP. Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells. Eur J Med Chem. 2010 Jun;45(6):2473-9. Epub 2010 Feb 18. PubMed PMID: 20219270.

120: Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist. 2010;15(3):236-45. Epub 2010 Mar 9. PubMed PMID: 20215359.

121: Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2010 Mar;10(3):305-17. Review. PubMed PMID: 20214511.

122: Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene. 2010 May 20;29(20):2938-49. Epub 2010 Mar 8. PubMed PMID: 20208561.

123: Dimou AT, Syrigos KN, Saif MW. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP. 2010 Mar 5;11(2):135-8. Review. PubMed PMID: 20208321.

124: Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M. mTOR pathway inhibition in renal cell carcinoma. Urol Oncol. 2010 Mar 4. [Epub ahead of print] PubMed PMID: 20207176.

125: Katta A, Fesler MJ, Tan A, Vuong G, Richart JM. Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy. Cancer Chemother Pharmacol. 2010 Jul;66(2):409-12. Epub 2010 Mar 5. PubMed PMID: 20204363.

126: Unno M. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors]. Nippon Shokakibyo Gakkai Zasshi. 2010 Mar;107(3):392-5. Review. Japanese. PubMed PMID: 20203442.

127: Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab. 2010 Mar;95(3):987-93. PubMed PMID: 20203334.

128: Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. Epub 2010 Mar 4. PubMed PMID: 20203173.

129: Rosen LS, Ashurst HL, Chap L. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist. 2010;15(3):216-35. Epub 2010 Mar 3. PubMed PMID: 20200040.

130: Bergmann L, Miller K. [Outlook: Future therapy of renal cell carcinoma]. Onkologie. 2010;33 Suppl 1:18-20. Epub 2010 Jan 22. German. PubMed PMID: 20164673.

131: Jäger E. [Monitoring of metastatic renal cell carcinoma--standards and challenges]. Onkologie. 2010;33 Suppl 1:15-7. Epub 2010 Jan 22. German. PubMed PMID: 20164672.

132: Marschner N. [Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma]. Onkologie. 2010;33 Suppl 1:12-4. Epub 2010 Jan 22. German. PubMed PMID: 20164671.

133: Gschwend JE. [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma]. Onkologie. 2010;33 Suppl 1:10-1. Epub 2010 Jan 22. Review. German. PubMed PMID: 20164670.

134: Miller K. [First-line therapy of metastatic renal cell carcinoma--update 2009]. Onkologie. 2010;33 Suppl 1:5-9. Epub 2010 Jan 22. Review. German. PubMed PMID: 20164669.

135: Bergmann L. [Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma]. Onkologie. 2010;33 Suppl 1:2-4. Epub 2010 Jan 22. Review. German. PubMed PMID: 20164668.

136: Bergmann L, Miller K. [The introduction of targeted drugs]. Onkologie. 2010;33 Suppl 1:1. Epub 2010 Jan 22. German. PubMed PMID: 20164667.

137: Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, Miller K, Sanders K, Short S, Sperinde J, Prasad G, Williams S, Kerbel R, Ebos J, Mutsaers A, Mendlein JD, Harris AS, Furfine ES. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs. 2010 Mar 25;2(2). [Epub ahead of print] PubMed PMID: 20190562.

138: Ravaud A, de la Fouchardière C, Asselineau J, Delord JP, Do Cao C, Niccoli P, Rodien P, Klein M, Catargi B. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist. 2010;15(2):212-3; author reply 214. PubMed PMID: 20189981.

139: Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer. 2010 Feb 24. [Epub ahead of print] PubMed PMID: 20188433.

140: Makita N, Miyakawa M, Fujita T, Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid. 2010 Mar;20(3):323-6. PubMed PMID: 20187785.

141: Hershman JM, Liwanpo L. How does sunitinib cause hypothyroidism? Thyroid. 2010 Mar;20(3):243-4. PubMed PMID: 20187779.

142: Ansari J, Glaholm J, McMenemin R, James ND, Hussain SA. Recent advances and future directions in the management of metastatic renal cell carcinoma. Anticancer Agents Med Chem. 2010 Mar;10(3):225-35. PubMed PMID: 20184547.

143: Ahlman H, Nilsson O, Nilsson B. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear]. Lakartidningen. 2009 Dec 9-21;106(50-51):3424-9. Review. Swedish. PubMed PMID: 20180446.

144: Herrmann E, Bierer S, Wülfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol. 2010 Jun;28(3):303-9. Epub 2010 Feb 24. PubMed PMID: 20180125.

145: Porta C. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'. Br J Cancer. 2010 Mar 30;102(7):1196-7. Epub 2010 Feb 23. PubMed PMID: 20179707; PubMed Central PMCID: PMC2853087.

146: Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol. 2010 Feb 23. [Epub ahead of print] PubMed PMID: 20179017.

147: Fournier C, Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J. 2010 Feb 15;16(2):17. PubMed PMID: 20178713.

148: Staehler M, Haseke N, Zilinberg K, Stadler T, Stief CG. Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy. Urol Int. 2010;84(1):119-21. Epub 2010 Feb 17. PubMed PMID: 20173383.

149: Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010 Apr;11(4):373-82. Epub 2010 Feb 18. Review. PubMed PMID: 20171141.

150: Haglund C, Aleskog A, Håkansson LD, Höglund M, Jacobsson S, Larsson R, Lindhagen E. The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicol Lett. 2010 May 4;194(3):102-7. Epub 2010 Feb 16. PubMed PMID: 20167269.

151: Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010 Feb;456(2):111-27. Epub 2010 Feb 18. Review. PubMed PMID: 20165865.

152: Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010 Feb 15. [Epub ahead of print] PubMed PMID: 20163917.

153: Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer. 2010 Feb 18;10:45. PubMed PMID: 20163744; PubMed Central PMCID: PMC2837011.

154: Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010 Feb 16. [Epub ahead of print] PubMed PMID: 20162573.

155: Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010 Jun;12(6):603-7. Epub 2010 Feb 14. PubMed PMID: 20156808.

156: Mashkani B, Griffith R, Ashman LK. Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem. 2010 Mar 1;18(5):1789-97. Epub 2010 Jan 28. PubMed PMID: 20156689.

157: Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Molinié V, Escudier B. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010 Feb 12. [Epub ahead of print] PubMed PMID: 20154303.

158: Minor DR. Risk of bleeding not increased by sorafenib or sunitinib. Lancet Oncol. 2010 Feb;11(2):112-3; author reply 113. PubMed PMID: 20152763.

159: Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, Canipari C. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010 May;77(9):809-15. Epub 2010 Feb 10. PubMed PMID: 20147887.

160: DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, Worrall JW, Diehl W, English JM, Wu JC. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance. J Biochem. 2010 Apr;147(4):601-9. Epub 2010 Feb 10. PubMed PMID: 20147452.

161: Woodrum C, Nobil A, Dabora SL. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med. 2010 Feb 10;8:14. PubMed PMID: 20146790; PubMed Central PMCID: PMC2834646.

162: O'Donnell PH, Jensen A, Posadas EM, Bridge JA, Yeldandi AV, Yang XJ, Stadler WM, Al-Ahmadie H. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010 Feb;7(2):110-4. PubMed PMID: 20145663.

163: van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer. 2010 Mar 2;102(5):803-9. Epub 2010 Feb 9. PubMed PMID: 20145618; PubMed Central PMCID: PMC2833256.

164: Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res. 2010 Feb 15;16(4):1216-25. Epub 2010 Feb 9. PubMed PMID: 20145174.

165: Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schöffski P. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid. 2010 Mar;20(3):317-22. PubMed PMID: 20144039.

166: Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. Am J Clin Oncol. 2010 May 3. [Epub ahead of print] PubMed PMID: 20142724.

167: Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Boyle MG, Trout A, Flaherty AM, Bajorin DF. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010 Mar 10;28(8):1373-9. Epub 2010 Feb 8. PubMed PMID: 20142593.

168: Oya M. [Renal cell carcinoma]. Gan To Kagaku Ryoho. 2010 Jan;37(1):29-31. Japanese. PubMed PMID: 20140991.

169: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):661-700. PubMed PMID: 20140276.

170: Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist. 2010;15(2):130-41. Epub 2010 Feb 5. Review. PubMed PMID: 20139170.

171: Ding W, Cai T, Zhu H, Wu R, Tu C, Yang L, Lu W, He Q, Yang B. Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett. 2010 Jul 28;293(2):158-66. Epub 2010 Feb 6. PubMed PMID: 20137855.

172: Grávalos C, Grande E, Gasent JM. The potential role of sunitinib in gastrointestinal cancers other than GIST. Crit Rev Oncol Hematol. 2010 Feb 2. [Epub ahead of print] PubMed PMID: 20133148.

173: Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC, Mehta MP. Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2010 Feb 2. [Epub ahead of print] PubMed PMID: 20133077.

174: Reichardt P, Blay JY, Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010 Feb;10(2):221-32. Review. PubMed PMID: 20131998.

175: Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs. 2010 Mar;15(1):13-26. Review. PubMed PMID: 20128706.

176: Mena AC, Pulido EG, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010 Jan;21 Suppl 1:S3-11. Review. PubMed PMID: 20110785.

177: Blesa JM, Pulido EG. Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient. Anticancer Drugs. 2010 Jan;21 Suppl 1:S23-6. PubMed PMID: 20110784.

178: Puente J, Manzano A, Martin M, López-Tarruella S, Díaz-Rubio E. Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. Anticancer Drugs. 2010 Jan;21 Suppl 1:S19-22. PubMed PMID: 20110783.

179: Calvo OF, Vázquez DD, López MR, Aparicio LM. Renal cell carcinoma: complete response. Anticancer Drugs. 2010 Jan;21 Suppl 1:S17-8. PubMed PMID: 20110782.

180: García-Campelo R, Quindós M, Vázquez DD, López MR, Carral A, Calvo OF, Soto JM, Grande E, Durana J, Antón-Aparicio LM. Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. Anticancer Drugs. 2010 Jan;21 Suppl 1:S13-5. PubMed PMID: 20110781.

181: Mena AC. Anti-cancer drugs. Editorial. Anticancer Drugs. 2010 Jan;21 Suppl 1:S1-2. PubMed PMID: 20110780.

182: Spencer J, Chowdhry BZ, Hamid S, Mendham AP, Male L, Coles SJ, Hursthouse MB. Seven 3-methylidene-1H-indol-2(3H)-ones related to the multiple-receptor tyrosine kinase inhibitor sunitinib. Acta Crystallogr C. 2010 Feb;66(Pt 2):o71-8. Epub 2010 Jan 15. PubMed PMID: 20124685.

183: Escudier B, Paparel P, Neuzillet Y, Long JA, Rioux-Leclercq N, Correas JM, Lang H, Poissonnier L, Baumert H, Mejean A, Patard JJ. [Treatment of metastatic kidney cancer in elderly subjects]. Prog Urol. 2009 Nov;19 Suppl 3:S129-32. French. PubMed PMID: 20123496.

184: Basille D, Andrejak M, Bentayeb H, Kanaan M, Fournier C, Lecuyer E, Boutemy M, Garidi R, Douadi Y, Dayen C. Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy. Ann Pharmacother. 2010 Feb;44(2):383-6. Epub 2010 Jan 5. PubMed PMID: 20118139.

185: Yang CH, Chuang CK, Hsieh JJ, Chang JW. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf. 2010 May;9(3):459-70. PubMed PMID: 20113155.

186: Papaetis GS, Syrigos KN. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev. 2010 Mar;29(1):151-70. Review. PubMed PMID: 20112054.

187: Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 2010 May;49(4):520-3. PubMed PMID: 20105087.

188: Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010 Feb 16;102(4):658-64. Epub 2010 Jan 26. PubMed PMID: 20104222; PubMed Central PMCID: PMC2837567.

189: Keefe SM, Cohen MA, Brose MS. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res. 2010 Feb 1;16(3):778-83. Epub 2010 Jan 26. Review. PubMed PMID: 20103668.

190: Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010 Feb 1;70(3):1063-71. Epub 2010 Jan 26. PubMed PMID: 20103651.

191: Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010 Feb 1;70(3):1053-62. Epub 2010 Jan 26. PubMed PMID: 20103629.

192: Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, Delehedde M, Copin MC, Lassalle P. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010 Jan;56(2):180-7. PubMed PMID: 20102396.

193: Zhang HM, Yu X, Greig MJ, Gajiwala KS, Wu JC, Diehl W, Lunney EA, Emmett MR, Marshall AG. Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry. Protein Sci. 2010 Apr;19(4):703-15. PubMed PMID: 20095048; PubMed Central PMCID: PMC2867011.

194: Tong TQ, Rohde D, Peter S. Progress in the management of advanced renal cell carcinoma (RCC). Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. Epub 2010 Jan 21. Review. PubMed PMID: 20094957.

195: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. PubMed PMID: 20094643.

196: Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol. 2010 May;21(5):1130-1. Epub 2010 Jan 21. PubMed PMID: 20093352.

197: Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, Rini B. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol. 2010 Jan 20. [Epub ahead of print] PubMed PMID: 20089567.

198: Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J. Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol. 2010 Jan;12(1):15-21. Review. PubMed PMID: 20080466.

199: Heng DY, Kollmannsberger C. Sunitinib. Recent Results Cancer Res. 2010;184:71-82. Review. PubMed PMID: 20072832.

200: Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, Xia M. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol. 2010 May 1;79(9):1272-80. Epub 2010 Jan 11. PubMed PMID: 20067776; PubMed Central PMCID: PMC2834878.

201: Qian JY, Guo L. Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicol In Vitro. 2010 Apr;24(3):960-72. Epub 2010 Jan 11. PubMed PMID: 20064605.

202: Liu SW, Guitart JG, Kuzel TM, Gandhi M, Lacouture M. Effect of sunitinib on renal cell carcinoma cutaneous metastasis. Int J Dermatol. 2009 Nov;48(11):1269-70. PubMed PMID: 20064194.

203: Pisters PW, Patel SR. Gastrointestinal stromal tumors: Current management. J Surg Oncol. 2010 Jan 8. [Epub ahead of print] PubMed PMID: 20063363.

204: Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res. 2010 Jan;8(1):35-45. Epub 2010 Jan 6. PubMed PMID: 20053726; PubMed Central PMCID: PMC2808420.

205: Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int. 2009 Dec;104(11):1585-9. Review. PubMed PMID: 20053190.

206: Nuijten M, Mickisch G. SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival. Br J Cancer. 2010 Jan 5;102(1):232-3; author reply 234-5. Erratum in: Br J Cancer. 2010 Mar 16;102(6):1078. PubMed PMID: 20051962; PubMed Central PMCID: PMC2813753.

207: van der Veldt AA, de Boer MP, Boven E, Eringa EC, van den Eertwegh AJ, van Hinsbergh VW, Smulders YM, Serné EH. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs. 2010 Apr;21(4):439-46. PubMed PMID: 20051825.

208: Bello CL, Garrett M, Sherman L, Smeraglia J, Ryan B, Toh M. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol. 2010 Jan 5. [Epub ahead of print] PubMed PMID: 20049443.

209: Nishida T, Takahashi T, Miyazaki Y. Gastrointestinal stromal tumor: a bridge between bench and bedside. Gastric Cancer. 2009;12(4):175-88. Epub 2010 Jan 5. Review. PubMed PMID: 20047122.

210: Schallier D, Trullemans F, Fontaine C, Decoster L, De Greve J. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res. 2009 Dec;29(12):5225-8. PubMed PMID: 20044640.

211: Robert F, Sandler A, Schiller JH, Liu G, Harper K, Verkh L, Huang X, Ilagan J, Tye L, Chao R, Traynor AM. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2009 Dec 31. [Epub ahead of print] PubMed PMID: 20043166.

212: Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer. 2009 Dec 28;127(5):1197-1208. [Epub ahead of print] PubMed PMID: 20039326.

213: Suzuki N, Yoshino S, Somura H, Ueno T, Oka M. [A case of rapid growth GIST successfully treated with resection after long-term use of imatinib]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2354-6. Japanese. PubMed PMID: 20037420.

214: Kessler T, Bayer M, Schwöppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical Phase III and beyond. Recent Results Cancer Res. 2010;180:137-63. Review. PubMed PMID: 20033382.

215: Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010 Mar;5(3):354-60. PubMed PMID: 20032789.

216: Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, Verkh L, Huang X, Kern KA, Miller K. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol. 2010 Jul;21(7):1436-41. Epub 2009 Dec 23. PubMed PMID: 20032126; PubMed Central PMCID: PMC2890319.

217: Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol. 2010 Feb;40(2):101-6. Epub 2009 Dec 23. Review. PubMed PMID: 20031962.

218: Faris JE, Michaelson MD. Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC. Nat Rev Clin Oncol. 2010 Jan;7(1):7-8. PubMed PMID: 20029441.

219: Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010 Jan;194(1):157-65. PubMed PMID: 20028918.

220: Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. Review. PubMed PMID: 20028613.

221: Di Lorenzo G, Autorino R. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34. J Urol. 2010 Feb;183(2):824-5; author reply 825. Epub 2009 Dec 21. PubMed PMID: 20022057.

222: Liamina IV, Starikova EA, Kuznetsova SA, Kiseleva EP, Freĭdlin IS. [Effect of sutent and celecoxib on the properties of endothelial cells in vitro]. Vopr Onkol. 2009;55(5):603-7. Russian. PubMed PMID: 20020657.

223: Guevremont C, Mija FI, Isbarn H, Jeldres C, Lughezzani G, Sun M, Audet P, Perrotte P, Karakiewicz PI. Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases. Can Urol Assoc J. 2009 Dec;3(6):E92-3. PubMed PMID: 20019964; PubMed Central PMCID: PMC2792436.

224: Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant. 2010 Mar;25(3):1001-3. Epub 2009 Dec 16. PubMed PMID: 20019017.

225: Gu Y, Zhao W, Meng F, Qu B, Zhu X, Sun Y, Shu Y, Xu Q. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol. 2010 Apr;135(1):55-62. Epub 2009 Dec 16. PubMed PMID: 20015695.

226: van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, Hogendoorn PC, van der Burg SH, Gelderblom H, van Hall T. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010 Aug 15;127(4):899-909. PubMed PMID: 20013807.

227: Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010 Mar;13(1):1-14. Epub 2009 Dec 11. PubMed PMID: 20012482; PubMed Central PMCID: PMC2845892.

228: Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther. 2010 Jan;9(1):15-9. Epub 2010 Jan 17. PubMed PMID: 20009542.

229: Gramza AW, Corless CL, Heinrich MC. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2009 Dec 15;15(24):7510-7518. PubMed PMID: 20008851.

230: Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010 Feb 18;115(7):1425-32. Epub 2009 Dec 10. PubMed PMID: 20007803; PubMed Central PMCID: PMC2826764.

231: Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, Salih HR. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol. 2009 Dec 15;183(12):8286-94. PubMed PMID: 20007592.

232: Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010 Jan;46(2):439-48. Epub 2009 Dec 16. Review. PubMed PMID: 20006922.

233: Zeng H, Li X, Yao J, Zhu Y, Liu J, Yang Y, Qiang W. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol Int. 2009;83(4):482-5. Epub 2009 Dec 8. PubMed PMID: 19996660.

234: Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology. 2010;220(1):77-81. Epub 2009 Dec 9. Review. PubMed PMID: 19996579.

235: Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71. Epub 2009 Dec 5. Review. PubMed PMID: 19967539.

236: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):541-57. PubMed PMID: 19967103.

237: Pwint TP, Macaulay V, Roberts IS, Sullivan M, Protheroe A. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. 2009 Dec 3. [Epub ahead of print] PubMed PMID: 19962921.

238: Larkin J, Gore M. Health policy: The UK 'postcode lottery' in renal cell carcinoma. Nat Rev Urol. 2009 Dec;6(12):636-8. PubMed PMID: 19956190.

239: Tamaskar I, Pili R. Update on novel agents in renal cell carcinoma. Expert Rev Anticancer Ther. 2009 Dec;9(12):1817-27. Review. PubMed PMID: 19954293.

240: Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. Review. PubMed PMID: 19954291.

241: Bossung V, Harbeck N. Angiogenesis inhibitors in the management of breast cancer. Curr Opin Obstet Gynecol. 2010 Feb;22(1):79-86. Review. PubMed PMID: 19952746.

242: Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs. 2010 Feb;21(2):206-9. PubMed PMID: 19952730.

243: Pastorelli D, Zustovich F, Faggioni G, Zovato S, Donach M, Nicoletto O, Farina M, Furini L, Ceravolo R, Carli P, Lombardi G. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma. Anticancer Drugs. 2010 Feb;21(2):210-3. PubMed PMID: 19952729.

244: Kleiman M, Sagi Y, Bloch N, Agur Z. Use of virtual patient populations for rescuing discontinued drug candidates and for reducing the number of patients in clinical trials. Altern Lab Anim. 2009 Sep;37 Suppl 1:39-45. PubMed PMID: 19807203.

245: Agaimy A, Schneider-Stock R. [Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy]. Pathologe. 2010 Mar;31(2):115-22. Review. German. PubMed PMID: 19949796.

246: Wood LS. Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs. 2009 Dec;13 Suppl:13-8. Review. PubMed PMID: 19948455.

247: Thompson JA. Metastatic renal cell carcinoma: current standards of care. Clin J Oncol Nurs. 2009 Dec;13 Suppl:8-12. Review. PubMed PMID: 19948454.

248: Ravaud A, Digue L, Trufflandier N, Smith D. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol. 2010 Feb;21(2):431-2. Epub 2009 Nov 26. PubMed PMID: 19945958.

249: Choueiri TK, Atkins MB. Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit? Nat Rev Clin Oncol. 2009 Dec;6(12):679-80. PubMed PMID: 19942921.

250: Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):713-22. Review. PubMed PMID: 19942148.

251: Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. Gerontology. 2010;56(3):303-9. Epub 2009 Nov 26. PubMed PMID: 19940466.

252: Miller RE, Larkin JM. Combination systemic therapy for advanced renal cell carcinoma. Oncologist. 2009 Dec;14(12):1218-24. Epub 2009 Nov 25. Review. PubMed PMID: 19939892.

253: Siebels M, Staehler M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H; Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT). [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)]. Aktuelle Urol. 2010 Mar;41(2):122-30. Epub 2009 Nov 20. German. PubMed PMID: 19937556.

254: Hohenberger P. [Aspects of surgical treatment for gastro-intestinal stromal tumors]. Radiologe. 2009 Dec;49(12):1122-7. Review. German. PubMed PMID: 19937425.

255: Vasamiliette J, Hohenberger P, Schoenberg S, Diehl S, Dinter DJ, Marx A, Stroebel P, Strauss LG, Dimitrakopoulou-Strauss A. Treatment monitoring with 18F-FDG PET in metastatic thymoma after 90Y-Dotatoc and selective internal radiation treatment (SIRT). Hell J Nucl Med. 2009 Sep-Dec;12(3):271-3. PubMed PMID: 19936342.

256: de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2010 Mar 11;51(4):934-41. Epub 2009 Oct 31. PubMed PMID: 19931354.

257: Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology. 2010 May;75(5):1108-13.e1. Epub 2009 Nov 20. PubMed PMID: 19931124.

258: Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257-71. Epub 2009 Nov 16. Review. PubMed PMID: 19923864.

259: Huang X, Patel S, Ahmed N, Seiter K, Liu D. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther. 2009 Feb 6;2:215-9. PubMed PMID: 19920908; PubMed Central PMCID: PMC2761170.

260: Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010 Jan 5;102(1):80-6. Epub 2009 Nov 17. PubMed PMID: 19920817; PubMed Central PMCID: PMC2813739.

261: Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, Moxhon A, Duprez T, Guigay J. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010 Jan 1;28(1):21-8. Epub 2009 Nov 16. PubMed PMID: 19917865.

262: Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev. 2010 Feb;36(1):63-8. Epub 2009 Nov 14. Review. PubMed PMID: 19914780.

263: Kerbel RS. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast. 2009 Oct;18 Suppl 3:S41-7. Review. PubMed PMID: 19914541.

264: Raymond E, Faivre S, Hammel P, Ruszniewski P. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol. 2009 Dec;4(4):253-4. Epub 2009 Nov 13. PubMed PMID: 19911111.

265: Bond M, Hoyle M, Moxham T, Napier M, Anderson R. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. Health Technol Assess. 2009 Sep;13 Suppl 2:69-74. Review. PubMed PMID: 19804692.

266: Mowatt G, Boachie C, Crowther M, Fraser C, Hernández R, Jia X, Ternent L. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. Health Technol Assess. 2009 Sep;13 Suppl 2:63-8. Review. PubMed PMID: 19804691.

267: Perez-Gracia JL, Prior C, Guillén-Grima F, Segura V, Gonzalez A, Panizo A, Melero I, Grande-Pulido E, Gurpide A, Gil-Bazo I, Calvo A. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer. 2009 Dec 1;101(11):1876-83. Epub 2009 Nov 10. PubMed PMID: 19904265; PubMed Central PMCID: PMC2788252.

268: Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009 Nov 15;15(22):7045-52. Epub 2009 Nov 10. PubMed PMID: 19903787.

269: Aragon-Ching JB, Dahut WL. About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? Ann Oncol. 2010 Jan;21(1):183-4. Epub 2009 Nov 10. PubMed PMID: 19903718.

270: Faivre SJ, Bouattour M, Dreyer C, Raymond E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol. 2009 Dec 10;27(35):e248-50; author reply e251-2. Epub 2009 Nov 9. PubMed PMID: 19901099.

271: Luo X, Cappelleri JC, Cella D, Li JZ, Charbonneau C, Kim ST, Chen I, Motzer RJ. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale. Value Health. 2009 Jun;12(4):580-6. Epub 2008 Nov 11. PubMed PMID: 19900256.

272: Wolter P, Schöffski P. Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. Acta Oncol. 2010;49(1):13-23. Review. PubMed PMID: 19900123.

273: Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb;17(2):407-15. Epub 2009 Nov 7. PubMed PMID: 19898902.

274: Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol. 2010 Mar;40(3):194-202. Epub 2009 Nov 7. PubMed PMID: 19897852.

275: Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2010 Mar 11;51(4):958-64. Epub 2009 Oct 12. PubMed PMID: 19896317; PubMed Central PMCID: PMC2814903.

276: Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. 2009;23(6):377-89. doi: 10.2165/11318860-000000000-00000. PubMed PMID: 19894779.

277: Miksad RA, Lai KC, Stein MC, Healy ME, Rojas R, Krajewski KM, Zhu AX. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. J Gastrointest Cancer. 2009;40(3-4):119-22. PubMed PMID: 19894033.

278: Sonpavde G, Hutson TE. Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. Clin Genitourin Cancer. 2008 Dec;6 Suppl 1:S29-36. Review. PubMed PMID: 19891127.

279: Chung EK, Stadler WM. Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. Clin Genitourin Cancer. 2008 Dec;6 Suppl 1:S22-8. Review. PubMed PMID: 19891126.

280: Bukowski RM. What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic renal cell carcinoma? Clin Genitourin Cancer. 2008 Dec;6 Suppl 1:S14-21. Review. PubMed PMID: 19891125.

281: Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer. 2008 Dec;6 Suppl 1:S7-13. Review. PubMed PMID: 19891124.

282: Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer. 2009;12(3):132-41. Epub 2009 Nov 5. Review. PubMed PMID: 19890692.

283: Breau RH, Leibovich BC. Therapy for metastatic RCC--questions remain. Nat Rev Urol. 2009 Nov;6(11):580-1. PubMed PMID: 19890336.

284: Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 2010 Jan;21(1):184-5. Epub 2009 Nov 4. PubMed PMID: 19889617.

285: Thiam R, Fournier LS, Trinquart L, Medioni J, Chatellier G, Balvay D, Escudier B, Dromain C, Cuenod CA, Oudard S. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010 May;21(5):936-41. Epub 2009 Nov 4. PubMed PMID: 19889607.

286: Lee SL, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptmann G, Ingham P, Cao Y. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19485-90. Epub 2009 Nov 3. PubMed PMID: 19887629; PubMed Central PMCID: PMC2780785.

287: Bugalho MJ, Domingues R, Borges A. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib. Oncologist. 2009 Nov;14(11):1083-7. Epub 2009 Nov 3. PubMed PMID: 19887470.

288: Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond). 2009 Nov 9;118(4):241-7. Review. PubMed PMID: 19886867.

289: Edeline J, Laguerre B, Rolland Y, Patard JJ. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2010 Jan;21(1):186-7. Epub 2009 Oct 29. PubMed PMID: 19875754.

290: Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010 May;105(9):1247-54. Epub 2009 Oct 26. PubMed PMID: 19863525.

291: Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res. 2009 Nov 15;15(22):6862-70. Epub 2009 Oct 27. PubMed PMID: 19861442; PubMed Central PMCID: PMC2783687.

292: Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res. 2009 Nov 15;15(22):6790-9. Epub 2009 Oct 27. PubMed PMID: 19861435; PubMed Central PMCID: PMC2783876.

293: Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009 Oct 27;2:45. Review. PubMed PMID: 19860903; PubMed Central PMCID: PMC2775749.

294: Wilkes GM. Drug essentials. Small molecule multitargeted TKI therapy. Oncology (Williston Park). 2008 Oct;22(11 Suppl Nurse Ed):47-8. PubMed PMID: 19856581.

295: Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009 Nov 17;101(10):1717-23. Epub 2009 Oct 20. PubMed PMID: 19844230; PubMed Central PMCID: PMC2768111.

296: Al Enazi MM, Kadry R, Mitwali H. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma. J Am Acad Dermatol. 2009 Nov;61(5):905-6. PubMed PMID: 19836653.

297: Abe F, Younos I, Westphal S, Samson H, Scholar E, Dafferner A, Hoke TA, Talmadge JE. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. Int Immunopharmacol. 2010 Jan;10(1):140-5. Epub 2009 Oct 12. PubMed PMID: 19833232.

298: Wozel G, Sticherling M, Schön MP. Cutaneous side effects of inhibition of VEGF signal transduction. J Dtsch Dermatol Ges. 2010 Apr;8(4):243-9. Epub 2009 Oct 13. English, German. PubMed PMID: 19832927.

299: Karaca H, Lale A, Dikilitas M, Ozkan M, Er O. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Med Oncol. 2009 Oct 15. [Epub ahead of print] PubMed PMID: 19830602.

300: Merseburger AS, Simon A, Waalkes S, Kuczyk MA. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther. 2009 Oct;9(10):1429-34. Review. PubMed PMID: 19828003.

301: Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer. 2009 Nov 3;101(9):1543-8. Epub 2009 Oct 13. PubMed PMID: 19826424; PubMed Central PMCID: PMC2778527.

302: Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9. Epub 2009 Oct 13. PubMed PMID: 19826129.

303: Passarella RJ, Zhou L, Phillips JG, Wu H, Hallahan DE, Diaz R. Recombinant peptides as biomarkers for tumor response to molecular targeted therapy. Clin Cancer Res. 2009 Oct 15;15(20):6421-9. Epub 2009 Oct 13. PubMed PMID: 19825959; PubMed Central PMCID: PMC2763341.

304: Preusser M, Hutterer M, Sohm M, Koperek O, Elandt K, Dieckmann K, Prayer D, Marosi C. Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol. 2010 Apr;97(2):305-8. Epub 2009 Oct 10. PubMed PMID: 19820899.

305: Swanton C, Burrell RA. Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity. Cancer Biol Ther. 2009 Nov;8(21):2051-3. PubMed PMID: 19816149.

306: Choueiri TK, Mosquera JM, Hirsch MS. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer. 2009 Oct;7(3):E93-4. PubMed PMID: 19815489.

307: Vickers MM, Heng DY, Hemmelgarn B, Eigl BJ. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009 Oct;7(3):E104-6. PubMed PMID: 19815480.

308: Hensley ML, Sill MW, Scribner DR Jr, Brown J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR, Gehrig PA. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2009 Dec;115(3):460-5. Epub 2009 Oct 6. PubMed PMID: 19811811; PubMed Central PMCID: PMC2783261.

309: Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C. Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res. 2009 Oct 7;28:134. Review. PubMed PMID: 19811659; PubMed Central PMCID: PMC2764641.

310: Gkialas IK, Papadopoulos G. New therapeutic approaches in the management of metastatic renal cell carcinoma. J BUON. 2009 Jul-Sep;14(3):399-404. Review. PubMed PMID: 19810129.

311: Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, Stein K. Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma. Value Health. 2009 Sep 25. [Epub ahead of print] PubMed PMID: 19804431.

312: D'Adamo D. Advances in the treatment of gastrointestinal stromal tumor. Adv Ther. 2009 Sep;26(9):826-37. Epub 2009 Oct 2. Review. PubMed PMID: 19802531.

313: Bar-Sela G, Kedem E, Hadad S, Pollack S, Haim N, Atrash F, Shahar E. Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. Jpn J Clin Oncol. 2010 Feb;40(2):163-5. Epub 2009 Oct 1. PubMed PMID: 19797416.

314: Etienne-Grimaldi MC, Renée N, Izzedine H, Milano G. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3757-61. Epub 2009 Sep 17. PubMed PMID: 19797000.

315: Ramsey S. The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer. Mol Diagn Ther. 2009;13(5):277-81. doi: 10.2165/11315860-000000000-00000. Review. PubMed PMID: 19791832.

316: Garnock-Jones KP, Keating GM. Everolimus: in advanced renal cell carcinoma. Drugs. 2009 Oct 22;69(15):2115-24. doi: 10.2165/11203770-000000000-00000. PubMed PMID: 19791829.

317: Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol. 2010 Apr;50(4):472-81. Epub 2009 Sep 24. PubMed PMID: 19779038.

318: Higgins MJ, Forastiere A, Marur S. New directions in the systemic treatment of metastatic thyroid cancer. Oncology (Williston Park). 2009 Aug;23(9):768-75. Review. PubMed PMID: 19777762.

319: George S, Bukowski RM. Role of everolimus in the treatment of renal cell carcinoma. Ther Clin Risk Manag. 2009 Oct;5(5):699-706. Epub 2009 Sep 15. PubMed PMID: 19774211; PubMed Central PMCID: PMC2747388.

320: Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. Epub 2009 Sep 22. PubMed PMID: 19773380; PubMed Central PMCID: PMC2774722.

321: Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6277-83. Epub 2009 Sep 22. PubMed PMID: 19773375; PubMed Central PMCID: PMC2756318.

322: Song IC, Lim JS, Yun HJ, Kim S, Kang DY, Lee HJ. Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment. Jpn J Clin Oncol. 2009 Dec;39(12):833-6. Epub 2009 Sep 22. PubMed PMID: 19773269.

323: Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009 Oct;10(10):967-74. Epub 2009 Sep 18. Review. PubMed PMID: 19767240.

324: Zhong H, Tran LM, Stang JL. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. J Mol Graph Model. 2009 Nov;28(4):336-46. Epub 2009 Aug 31. PubMed PMID: 19767223.

325: Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009 Sep 15;23(18):2152-65. PubMed PMID: 19759263; PubMed Central PMCID: PMC2751988.

326: Kalantari HR. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2009 Oct 6;101(7):1222-3; author reply 1224. Epub 2009 Sep 15. PubMed PMID: 19755985; PubMed Central PMCID: PMC2768102.

327: Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009 Nov;8(21):2042-50. Epub 2009 Nov 7. PubMed PMID: 19755855; PubMed Central PMCID: PMC2833355.

328: Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets. 2009 Sep;9(6):738-47. PubMed PMID: 19754358.

329: Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. New treatment approaches in renal cell carcinoma. Anticancer Drugs. 2009 Nov;20(10):893-900. Review. PubMed PMID: 19752718.

330: Di Lorenzo G, Autorino R, Sternberg CN. Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. Eur Urol. 2009 Sep 8. [Epub ahead of print] PubMed PMID: 19748725.

331: Rossi A, Maione P, Ferrara ML, Sacco PC, Schettino C, Bareschino MA, Gridelli C. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. Curr Med Chem. 2009;16(30):3919-30. Review. PubMed PMID: 19747132.

332: Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs. Prescrire Int. 2009 Aug;18(102):165. PubMed PMID: 19746526.

333: La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol. 2010 Jun;33(3):217-20. PubMed PMID: 19745694.

334: Liljegren A, Bergh J, Castany R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast. 2009 Aug;18(4):259-62. PubMed PMID: 19744626.

335: Cardoso F, Senkus-Konefka E. Sunitinib in breast cancer: friend or foe. Breast. 2009 Aug;18(4):211-2. PubMed PMID: 19744625.

336: Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010 Feb;116(2):163-7. Epub 2009 Sep 8. PubMed PMID: 19740535.

337: Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J. 2009 Oct 23;424(1):47-60. PubMed PMID: 19740074.

338: Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res. 2009 Sep 15;15(18):5869-77. Epub 2009 Sep 8. PubMed PMID: 19737953.

339: Blanke CD. Biomarkers in GIST: partly ready for prime-time use. Clin Cancer Res. 2009 Sep 15;15(18):5603-5. Epub 2009 Sep 8. PubMed PMID: 19737947.

340: Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15;15(18):5902-9. Epub 2009 Sep 8. PubMed PMID: 19737946.

341: Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009 Oct;6(10):569-79. Epub 2009 Sep 8. Review. PubMed PMID: 19736552.

342: Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48(7):964-70. Review. PubMed PMID: 19734999.

343: Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP. 2009 Sep 4;10(5):523-7. PubMed PMID: 19734629.

344: van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5. Review. PubMed PMID: 19733976.

345: Kreze A Jr, Stáhalová V, Zadrazilová A, Koskuba J, Kosák M. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature]. Klin Onkol. 2009;22(4):176-8. Slovak. PubMed PMID: 19731880.

346: Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2009 Sep 3. [Epub ahead of print] PubMed PMID: 19730791.

347: Cersosimo RJ. Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. Am J Health Syst Pharm. 2009 Sep 15;66(18):1625-33. Review. PubMed PMID: 19729567.

348: Li XG, Wang GF, Zhang JY, Wu SY, Xu W, Wu SG, Zhang JJ. [Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors]. Nan Fang Yi Ke Da Xue Xue Bao. 2009 Aug;29(8):1612-4. Chinese. PubMed PMID: 19726307.

349: Hyodo F, Chandramouli GV, Matsumoto S, Matsumoto K, Mitchell JB, Krishna MC, Munasinghe JP. Estimation of tumor microvessel density by MRI using a blood pool contrast agent. Int J Oncol. 2009 Oct;35(4):797-804. PubMed PMID: 19724915.

350: Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia. 2009 Sep;11(9):910-20. PubMed PMID: 19724685; PubMed Central PMCID: PMC2735805.

351: Schlemmer M, Sourbron SP, Schinwald N, Nikolaou K, Becker CR, Reiser MF, Berger F. Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. Eur J Radiol. 2009 Aug 29. [Epub ahead of print] PubMed PMID: 19720488.

352: Viguier JB, Amraoui S, Solanilla A, Boulon C, Constans J, Conri C. [An image of vena cava thrombosis]. J Mal Vasc. 2009 Nov;34(5):372-3. Epub 2009 Aug 29. French. PubMed PMID: 19717254.

353: Zołnierek J, Nurzyński P, Langiewicz P, Oborska S, Waśko-Grabowska A, Kuszatal E, Obrocka B, Szczylik C. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol. 2010 Mar;136(3):371-8. Epub 2009 Aug 27. PubMed PMID: 19711099.

354: Cersosimo RJ. Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1. Am J Health Syst Pharm. 2009 Sep 1;66(17):1525-36. Review. PubMed PMID: 19710436.

355: Himmelsbach K, Sauter D, Baumert TF, Ludwig L, Blum HE, Hildt E. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut. 2009 Dec;58(12):1644-53. Epub 2009 Aug 25. PubMed PMID: 19710032.

356: Yoon SY, Kim SY, Cho YH, Chung HW, So Y, Lee HM. Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT. Cancer Res Treat. 2009 Jun;41(2):100-3. Epub 2009 Jun 30. PubMed PMID: 19707508; PubMed Central PMCID: PMC2731211.

357: Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat. 2009 Jun;41(2):67-72. Epub 2009 Jun 30. PubMed PMID: 19707503; PubMed Central PMCID: PMC2731208.

358: Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 2009 Oct;6(10):596-603. Epub 2009 Aug 25. Review. PubMed PMID: 19707193.

359: Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009 Oct 10;27(29):4865-73. Epub 2009 Aug 24. Review. PubMed PMID: 19704059.

360: Reichardt P. [Internal medical therapy of gastrointestinal stroma tumors]. Radiologe. 2009 Dec;49(12):1128-31. Review. German. PubMed PMID: 19701624.

361: Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev. 2009 Dec;35(8):733-7. Epub 2009 Aug 21. Review. PubMed PMID: 19699588.

362: Ploner F, Eisterer W. [Treatment of extensive disease]. Wien Med Wochenschr. 2009;159(15-16):403-7. Review. German. PubMed PMID: 19696985.

363: James N, Pascoe J, Zachariah A, Ray D, Oldroyd A, Parry H, Benghiat H, Karina M, Collins S, Porfiri E. Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors. Clin Oncol (R Coll Radiol). 2009 Oct;21(8):610-6. Epub 2009 Aug 19. PubMed PMID: 19695849.

364: Clement JM, McDermott DF. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009 Aug;7(2):E7-9. Review. PubMed PMID: 19692326.

365: Jafri M, Porfiri E. A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed? Clin Genitourin Cancer. 2009 Aug;7(2):E42-4. PubMed PMID: 19692324.

366: Ansari J, Doherty A, McCafferty I, Wallace M, Deshmukh N, Porfiri E. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer. 2009 Aug;7(2):E39-41. PubMed PMID: 19692322.

367: Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009 Jun;10(5):470-81. Review. PubMed PMID: 19689244.

368: Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, Busato F, Di Battista M, Farsad M, Lodi F, Boschi S, Fanti S, Biasco G. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009 May-Jun;95(3):382-4. PubMed PMID: 19688982.

369: Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res Treat. 2008 Dec;40(4):211-3. Epub 2008 Dec 31. PubMed PMID: 19688133; PubMed Central PMCID: PMC2697472.

370: Xu X, Yang G, Zhang H, Prestwich GD. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Mediat. 2009 Sep;89(3-4):140-6. Epub 2009 Aug 12. Review. PubMed PMID: 19682598; PubMed Central PMCID: PMC2756011.

371: Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol. 2010 Feb;21(2):208-15. Epub 2009 Aug 12. Review. PubMed PMID: 19675092.

372: Adjallé R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009 Sep;41(9):687-96. Epub 2009 Aug 11. Review. PubMed PMID: 19672813.

373: Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009 Jul-Aug;15(4):263-8. Review. PubMed PMID: 19672141.

374: Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther. 2009 Aug;8(8):2193-203. Epub 2009 Aug 11. PubMed PMID: 19671760; PubMed Central PMCID: PMC2728155.

375: Theou-Anton N, Faivre S, Dreyer C, Raymond E. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf. 2009;32(9):717-34. doi: 10.2165/00002018-200932090-00003. Review. PubMed PMID: 19670913.

376: Merseburger AS, Waalkes S, Kuczyk MA. [Current state of systemic therapy of metastatic renal cell carcinoma]. Urologe A. 2009 Sep;48(9):983-4, 986, 988-9. Review. German. PubMed PMID: 19669118.

377: van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009 Sep 10;27(26):4406-12. Epub 2009 Aug 10. Erratum in: J Clin Oncol. 2010 Jun 1;28(16):2805. PubMed PMID: 19667267.

378: Vogelzang NJ, Samlowski W, Weissman A. Long-term response in primary renal cancer to sequential antiangiogenic therapy. J Clin Oncol. 2009 Sep 10;27(26):e106-7. Epub 2009 Aug 10. PubMed PMID: 19667262.

379: Kirkali Z, Tüzel E. Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? Future Oncol. 2009 Aug;5(6):871-88. Review. PubMed PMID: 19663736.

380: Nishioka C, Ikezoe T, Yang J, Yokoyama A. Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3). Leukemia. 2009 Nov;23(11):2171-3. Epub 2009 Aug 6. PubMed PMID: 19657366.

381: Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, Andreiuolo F, Marselos M. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol. 2010 Mar;65(4):649-60. Epub 2009 Aug 5. PubMed PMID: 19655144.

382: Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009 Oct 1;114(14):2984-92. Epub 2009 Aug 4. PubMed PMID: 19654408; PubMed Central PMCID: PMC2756206.

383: Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 1;27(25):4068-75. Epub 2009 Aug 3. PubMed PMID: 19652072.

384: Di Lorenzo G, Cartenì G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009 Sep 20;27(27):4469-74. Epub 2009 Aug 3. PubMed PMID: 19652053.

385: Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2009 Aug 4. [Epub ahead of print] PubMed PMID: 19649772.

386: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jun;31(5):341-56. PubMed PMID: 19649342.

387: Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist. 2009 Aug;14(8):800-5. Epub 2009 Aug 1. Review. Erratum in: Oncologist. 2009 Sep;14(9):949. PubMed PMID: 19648603.

388: Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 2009 Aug-Oct;12(4-5):114-26. Epub 2009 Aug 3. Review. PubMed PMID: 19648052.

389: Forner A, Llovet JM, Bruix J. Sunitinib and the benefits of a negative study. Lancet Oncol. 2009 Aug;10(8):743-4. Review. PubMed PMID: 19647195.

390: Park CY. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Anticancer Drugs. 2009 Oct;20(9):848-9. PubMed PMID: 19644356.

391: Fokt RM, Templeton A, Gillessen S, Ohlschlegel C, Schmid HP. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int. 2009;83(1):122-4. Epub 2009 Jul 27. Review. PubMed PMID: 19641373.

392: Lainakis G, Bamias A, Psimenou E, Fountzilas G, Dimopoulos MA. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. Clin Nephrol. 2009 Jul;72(1):73-8. PubMed PMID: 19640391.

393: Piñar D, Boix E, Meana JA, Herrero J. Sunitinib-induced thyrotoxicosis. J Endocrinol Invest. 2009 Dec;32(11):941-2. Epub 2009 Jul 28. PubMed PMID: 19636224.

394: Sugawara M, Geffner DL, Martinez D, Hershman JM. Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):367-72. Review. PubMed PMID: 19633548.

395: Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010 Feb;21(2):319-24. Epub 2009 Jul 24. PubMed PMID: 19633050.

396: Pal SK, Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas. 2009 Aug 20;63(4):269-74. Epub 2009 Jul 25. Review. PubMed PMID: 19632796.

397: Bil J, Zapala L, Nowis D, Jakobisiak M, Golab J. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett. 2010 Feb 1;288(1):57-67. Epub 2009 Jul 25. PubMed PMID: 19632769.

398: Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol. 2009 Aug;20 Suppl 6:vi35-40. Review. PubMed PMID: 19617296; PubMed Central PMCID: PMC2712592.

399: Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Rao Lelsani PC, Yadav S, Awasthi S. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38. PubMed PMID: 19626587.

400: Wong AL, Chou N, Lee KM, Ang BW, Cheng CL, Lee SC. Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy. Ann Oncol. 2009 Sep;20(9):1605-6. Epub 2009 Jul 17. PubMed PMID: 19622509.

401: Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Miwa A, Hirakawa K. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer. 2010 Feb 15;126(4):1004-16. PubMed PMID: 19621385.

402: Shiba K, Matsumoto T, Hirota S. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1080-5. Review. Japanese. PubMed PMID: 19620796.

403: Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC. Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 2009 Sep;182(3):881-6. Epub 2009 Jul 17. PubMed PMID: 19616232.

404: Choueiri TK, Bellmunt J. Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncol. 2009 Aug;10(8):740. Epub 2009 Jul 15. Review. PubMed PMID: 19615941.

405: Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009 Aug;10(8):757-63. Epub 2009 Jul 15. PubMed PMID: 19615940.

406: Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol. 2009 Sep;21(5):445-54. Review. PubMed PMID: 19606034.

407: Giannopoulou E, Dimitropoulos K, Argyriou AA, Koutras AK, Dimitrakopoulos F, Kalofonos HP. An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Invest New Drugs. 2009 Jul 15. [Epub ahead of print] PubMed PMID: 19603143.

408: Melichar B. How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy? Oncology. 2009;77(2):82-91. Epub 2009 Jul 13. Review. PubMed PMID: 19602908.

409: Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, Welch J, Gridelli C. Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer. 2009 Sep;45(14):2473-87. Review. PubMed PMID: 19596191.

410: Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects. Curr Drug Metab. 2009 Jun 1. [Epub ahead of print] PubMed PMID: 19594406.

411: Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009 Aug;10(8):794-800. Epub 2009 Jul 6. PubMed PMID: 19586800.

412: Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin. 2009 Aug;25(8):2081-90. PubMed PMID: 19586325.

413: Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009 Aug;6(8):465-77. Epub 2009 Jul 7. Review. PubMed PMID: 19581909.

414: Staehler M, Haseke N, Zilinberg E, Stadler T, Karl A, Siebels M, Dürr HR, Siegert S, Jauch KW, Bruns CJ, Stief CG. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol. 2010 Mar-Apr;28(2):139-44. Epub 2009 Jul 3. PubMed PMID: 19576802.

415: Basso M, Cassano A, Barone C. A survey of therapy for advanced renal cell carcinoma. Urol Oncol. 2010 Mar-Apr;28(2):121-33. Epub 2009 Jul 3. Review. PubMed PMID: 19576800.

416: Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer. 2009 Jul 21;101(2):238-43. Epub 2009 Jun 30. Review. PubMed PMID: 19568242; PubMed Central PMCID: PMC2720220.

417: Bamias A, Lainakis G, Manios E, Koroboki E, Gyftaki R, Zakopoulos N, Dimopoulos MA. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother. 2009 Jun;21(3):347-50. PubMed PMID: 19567357.

418: Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009 Nov;161(5):1045-51. Epub 2009 May 5. PubMed PMID: 19558553.

419: Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw. 2009 Jun;7(6):659-65. Review. PubMed PMID: 19555587.

420: Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw. 2009 Jun;7(6):645-56. Review. PubMed PMID: 19555586.

421: Doğan S, Can IH, Sayn M, Ozer E, Bayz U, Yazici G, Samim EE. The nasal septum: an unusual presentation of metastatic renal cell carcinoma. J Craniofac Surg. 2009 Jul;20(4):1204-6. PubMed PMID: 19553840.

422: McBride D. New study sheds light on angiogenesis inhibitors. ONS Connect. 2009 Jun;24(6):21. PubMed PMID: 19552190.

423: Castellano D, del Muro XG, Pérez-Gracia JL, González-Larriba JL, Abrio MV, Ruiz MA, Pardo A, Guzmán C, Cerezo SD, Grande E. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol. 2009 Nov;20(11):1803-12. Epub 2009 Jun 23. PubMed PMID: 19549706; PubMed Central PMCID: PMC2768734.

424: Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs. 2009 Jun 24. [Epub ahead of print] PubMed PMID: 19547920.

425: Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010 Aug;28(4):523-8. Epub 2009 Jun 23. PubMed PMID: 19547919.

426: Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol. 2009 Aug;6(8):478-87. Epub 2009 Jun 23. Review. PubMed PMID: 19546865.

427: Wörns MA, Weinmann A, Schuchmann M, Galle PR. Systemic therapies in hepatocellular carcinoma. Dig Dis. 2009;27(2):175-88. Epub 2009 Jun 22. Review. PubMed PMID: 19546557.

428: Yoon SS, Stangenberg L, Lee YJ, Rothrock C, Dreyfuss JM, Baek KH, Waterman PR, Nielsen GP, Weissleder R, Mahmood U, Park PJ, Jacks T, Dodd RD, Fisher CJ, Ryeom S, Kirsch DG. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1207-16. PubMed PMID: 19545786; PubMed Central PMCID: PMC2733223.

429: Rivera F, Benounna M, Sánchez de la Nieta MD. Sunitinib-aggravated hypertension. J Hypertens. 2009 Jul;27(7):1502-3. PubMed PMID: 19542988.

430: Miyanaga N, Akaza H. [Sorafenib(Nexavar)]. Gan To Kagaku Ryoho. 2009 Jun;36(6):1029-33. Review. Japanese. PubMed PMID: 19542731.

431: Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol. 2009 Oct;20(10):1703-7. Epub 2009 Jun 19. PubMed PMID: 19542251.

432: Wu CF, Chuang WP, Li AH, Hsiao CH. Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement. J Chin Med Assoc. 2009 Jun;72(6):323-7. PubMed PMID: 19541568.

433: van der Veldt AA, Boven E, Bex A. Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523. J Urol. 2009 Aug;182(2):797; author reply 797-8. Epub 2009 Jun 18. PubMed PMID: 19539957.

434: Heldwein FL, Escudier B, Smyth G, Souto CA, Vallancien G. Metastatic renal cell carcinoma management. Int Braz J Urol. 2009 May-Jun;35(3):256-70. PubMed PMID: 19538761.

435: Agarwal N, Hussain M. Management of bladder cancer: current and emerging strategies. Drugs. 2009 Jun 18;69(9):1173-87. doi: 10.2165/00003495-200969090-00003. Review. PubMed PMID: 19537835.

436: Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer. 2009 Aug 1;115(15):3571-80. PubMed PMID: 19536893.

437: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PubMed PMID: 19536362.

438: Kumar S, Masood N, Shaikh AJ. Old disease, new targets--part-I, solid malignancies. J Pak Med Assoc. 2009 Jun;59(6):398-405. Review. PubMed PMID: 19534378.

439: Cortés-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol. 2009 Jun;11(6):349-55. Review. PubMed PMID: 19531449.

440: Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009 Jul;6(7):375-83. Epub 2009 Jun 16. Review. PubMed PMID: 19528960.

441: Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care. 2009 Sep;3(3):170-9. Review. PubMed PMID: 19528803.

442: Battistella M, Mateus C, Lassau N, Chami L, Boukoucha M, Duvillard P, Cribier B, Robert C. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol. 2010 Feb;24(2):199-203. Epub 2009 Jun 8. PubMed PMID: 19522717.

443: Seront E, Machiels JP. Targeted therapies in the treatment of advanced renal cell carcinoma. Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):146-56. Review. PubMed PMID: 19519537.

444: Berchem G, Dewilde S, Mahassen P. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer. Bull Soc Sci Med Grand Duche Luxemb. 2009;(1):7-9. PubMed PMID: 19514172.

445: Casneuf VF, Demetter P, Boterberg T, Delrue L, Peeters M, Van Damme N. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol Rep. 2009 Jul;22(1):105-13. PubMed PMID: 19513511.

446: Soulières D. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy? Curr Opin Support Palliat Care. 2009 Sep;3(3):153-6. Review. PubMed PMID: 19512932.

447: Brower V. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J Natl Cancer Inst. 2009 Jun 16;101(12):846-7. Epub 2009 Jun 9. PubMed PMID: 19509354.

448: Pennell NA, Mekhail T. Investigational agents in the management of non-small cell lung cancer. Curr Oncol Rep. 2009 Jul;11(4):275-84. Review. PubMed PMID: 19508832.

449: Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96. Epub 2009 May 13. PubMed PMID: 19505856.

450: Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89. Review. PubMed PMID: 19500769.

451: Ballardini P, Margutti G, Aliberti C, Manfredini R. Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. Clin Drug Investig. 2009;29(7):487-90. doi: 10.2165/00044011-200929070-00007. PubMed PMID: 19499966.

452: Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol. 2009 Jun;6(6):338-43. PubMed PMID: 19498412.

453: Blay JY, Reichardt P. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert Rev Anticancer Ther. 2009 Jun;9(6):831-8. Review. PubMed PMID: 19496720.

454: Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, Scotte F. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009 Jun;9(6):705-17. Review. PubMed PMID: 19496707.

455: Huang M, Liu X, DU Q, Yao X, Yin KS. Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice. Chin Med J (Engl). 2009 May 5;122(9):1061-6. PubMed PMID: 19493441.

456: Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584-90. Epub 2009 Jun 1. PubMed PMID: 19487381.

457: Stadler WM. Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 1;27(22):3573-4. Epub 2009 Jun 1. PubMed PMID: 19487371.

458: Fife DJ, Wu JJ, Behnam SE, Linden KG. Sunitinib-induced hand-foot syndrome: a new, distinct form. Clin Exp Dermatol. 2010 Mar;35(2):200-1. Epub 2009 May 26. PubMed PMID: 19486049.

459: English BC, Price DK, Figg WD. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy. Cancer Biol Ther. 2009 Jul;8(13):1214-25. Epub 2009 Jul 4. PubMed PMID: 19483467; PubMed Central PMCID: PMC2802271.

460: Shibuya M. Angiogenesis regulated by VEGF and its receptors and its clinical application. Rinsho Ketsueki. 2009 May;50(5):404-12. Review. PubMed PMID: 19483401.

461: Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol. 2009 Oct;19(5):338-43. Epub 2009 May 27. Review. PubMed PMID: 19481151.

462: Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 2009 Aug 15;115(16):3618-30. Review. PubMed PMID: 19479976.

463: Yoo C, Kim JE, Yoon SK, Kim SC, Ahn JH, Kim TW, Suh C, Lee JL. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. Sarcoma. 2009;2009:360875. Epub 2009 May 20. PubMed PMID: 19478954; PubMed Central PMCID: PMC2685913.

464: Wood L. First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from ASCO 2008. Curr Oncol. 2009 May;16 Suppl 1:S24-6. PubMed PMID: 19478904; PubMed Central PMCID: PMC2687808.

465: Kapoor A. Inhibition of mTOR in kidney cancer. Curr Oncol. 2009 May;16 Suppl 1:S33-9. PubMed PMID: 19478899; PubMed Central PMCID: PMC2687803.

466: Gan HK, Seruga B, Knox JJ. Targeted therapies for renal cell carcinoma: more gains from using them again. Curr Oncol. 2009 May;16 Suppl 1:S45-51. PubMed PMID: 19478898; PubMed Central PMCID: PMC2687802.

467: Kapoor A, Gharajeh A, Sheikh A, Pinthus J. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol. 2009 May;16 Suppl 1:S60-6. PubMed PMID: 19478895; PubMed Central PMCID: PMC2687799.

468: Guevremont C, Jeldres C, Perrotte P, Karakiewicz PI. Sorafenib in the management of metastatic renal cell carcinoma. Curr Oncol. 2009 May;16 Suppl 1:S27-32. PubMed PMID: 19478894; PubMed Central PMCID: PMC2687798.

469: Masugata H, Senda S, Himoto T, Okuyama H, Inukai M, Murao K, Hosomi N, Yukiiri K, Kohno M, Yamagami A, Kohno T, Goda F. Early detection of hypertension in a patient treated with sunitinib by measuring cardio-ankle vascular index. Tohoku J Exp Med. 2009;218(2):115-9. PubMed PMID: 19478467.

470: Kroep JR, Bovée JV, van der Molen AJ, Hogendoorn PC, Gelderblom H. Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. J Cutan Pathol. 2009 May;36(5):565-9. Epub 2008 Oct 6. Review. PubMed PMID: 19476525.

471: Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009 Sep;20(9):1535-42. Epub 2009 May 27. PubMed PMID: 19474115.

472: Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20;27(18):3027-35. Epub 2009 May 26. PubMed PMID: 19470923; PubMed Central PMCID: PMC2702235.

473: Cakir M, Grossman AB. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology. 2009;90(4):323-48. Epub 2009 May 25. Review. PubMed PMID: 19468197.

474: Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun;12(3):81-9. Epub 2009 May 20. Review. PubMed PMID: 19467916.

475: Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, Weber E, Grünwald V, Roth A, Leyvraz S. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009 Sep;45(13):2293-7. Epub 2009 May 19. PubMed PMID: 19467857.

476: Rothermundt CA, Omlin A, Gillessen S. 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer. Ann Oncol. 2009 Jun;20(6):1144-6. PubMed PMID: 19465428.

477: Ito Y, Kobayashi K. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab]. Gan To Kagaku Ryoho. 2009 May;36(5):726-9. Japanese. PubMed PMID: 19461171.

478: Bagi CM, Christensen J, Cohen DP, Roberts WG, Wilkie D, Swanson T, Tuthill T, Andresen CJ. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther. 2009 May;8(9):856-65. PubMed PMID: 19458500.

479: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46. PubMed PMID: 19455266.

480: Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Investig Drugs. 2009 Jun;18(6):821-34. Review. PubMed PMID: 19453268.

481: Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol. 2009;48(6):927-31. PubMed PMID: 19452305.

482: George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 1;27(19):3154-60. Epub 2009 May 18. PubMed PMID: 19451429; PubMed Central PMCID: PMC2716937.

483: Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009 Jul;182(1):29-34; discussion 34. Epub 2009 May 17. PubMed PMID: 19447417.

484: Phé V, Rouprêt M, Lechevallier E, Patard JJ. [What's new in 2008 in kidney cancer?]. Prog Urol. 2009 May;19 Suppl 2:S56-64. Review. French. PubMed PMID: 19447330.

485: Gregory T, Mir O, Medioni J, Augereau B, Oudard S. Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma. Med Oncol. 2010 Jun;27(2):446-8. Epub 2009 May 15. PubMed PMID: 19444655.

486: Schmidinger M, Bojic A, Vogl UM, Lamm W, Zielinski CC. Management of cardiac adverse events occurring with sunitinib treatment. Anticancer Res. 2009 May;29(5):1627-9. PubMed PMID: 19443377.

487: Vine KL, Matesic L, Locke JM, Ranson M, Skropeta D. Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008. Anticancer Agents Med Chem. 2009 May;9(4):397-414. Review. PubMed PMID: 19442041.

488: Burkitt K, Chun SY, Dang DT, Dang LH. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther. 2009 May 12. [Epub ahead of print] PubMed PMID: 19435875.

489: Schöffski P, Bukowski R, Flodgren P, Ravaud A. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. Ann Oncol. 2009 May;20 Suppl 1:i25-i30. PubMed PMID: 19430005.

490: Blay JY. New paradigms in gastrointestinal stromal tumour management. Ann Oncol. 2009 May;20 Suppl 1:i18-24. PubMed PMID: 19430004.

491: Bellmunt J. Future developments in renal cell carcinoma. Ann Oncol. 2009 May;20 Suppl 1:i13-17. PubMed PMID: 19430003.

492: Sternberg CN. Expanding the boundaries of clinical practice: building on experience with targeted therapies. Ann Oncol. 2009 May;20 Suppl 1:i1-6. PubMed PMID: 19430002.

493: Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Target Oncol. 2009 Apr;4(2):121-33. Epub 2009 May 6. Review. PubMed PMID: 19421832.

494: Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res. 2009 May 15;15(10):3384-95. Epub 2009 May 5. PubMed PMID: 19417025.

495: Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? Thyroid. 2009 May;19(5):539-40. PubMed PMID: 19416001.

496: Secasan CC. Prognostic markers and new, innovative treatments in renal cell carcinoma. Saudi J Kidney Dis Transpl. 2009 May;20(3):355-61. Review. PubMed PMID: 19414934.

497: Dudek AZ, Murthaiah PK, Franklin M, Truskinovsky AM. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor. Acta Oncol. 2010;49(1):101-4. PubMed PMID: 19412810.

498: Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia. 2009 May;11(5):426-35. PubMed PMID: 19412427; PubMed Central PMCID: PMC2671855.

499: Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009 May;14(5):478-88. Epub 2009 May 1. Review. PubMed PMID: 19411318.

500: Buess M. [New therapeutic opportunities in metastatic renal cell carcinoma]. Praxis (Bern 1994). 2009 Apr 29;98(9):481-6. Review. German. PubMed PMID: 19404907.

501: Skubitz KM, Manivel JC, Clohisy DR, Frolich JW. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol. 2009 Aug;64(3):635-40. Epub 2009 Apr 29. Review. PubMed PMID: 19404642.

502: Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol. 2009 May;20(5):966-7; author reply 967. PubMed PMID: 19403939.

503: Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol. 2009 May;20(5):913-20. PubMed PMID: 19403935; PubMed Central PMCID: PMC2674960.

504: Linehan WM, Pinto PA, Bratslavsky G, Pfaffenroth E, Merino M, Vocke CD, Toro JR, Bottaro D, Neckers L, Schmidt LS, Srinivasan R. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer. 2009 May 15;115(10 Suppl):2252-61. Review. PubMed PMID: 19402075; PubMed Central PMCID: PMC2720093.

505: Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2306-12. Review. PubMed PMID: 19402073.

506: Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2313-20. Review. PubMed PMID: 19402072.

507: Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Treatment selection for patients with metastatic renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2327-33. Review. PubMed PMID: 19402069; PubMed Central PMCID: PMC2762357.

508: Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy in renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2321-6. Review. PubMed PMID: 19402067.

509: Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer. 2009 May 15;115(10 Suppl):2355-60. PubMed PMID: 19402066.

510: Hutson TE, Figlin RA. Novel therapeutics for metastatic renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2361-7. Review. PubMed PMID: 19402059.

511: Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2368-75. Review. PubMed PMID: 19402058.

512: Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol. 2010 Jun;27(2):373-8. Epub 2009 Apr 28. PubMed PMID: 19399651.

513: Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, Nakajima K, Hirota S; Japanese Study Group on GIST. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol. 2009 Apr;14(2):143-9. Epub 2009 Apr 24. PubMed PMID: 19390946.

514: Bellmunt J, Flodgren P, Roigas J, Oudard S. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int. 2009 Jul;104(1):10-8. Epub 2009 Apr 21. Review. PubMed PMID: 19388982.

515: Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, Semmler W, Kiessling F. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging. 2009 May;29(5):1125-33. PubMed PMID: 19388117.

516: Chen A, Agarwal N. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J. 2009 May;39(5):341-2. Epub 2009 Apr 20. PubMed PMID: 19382984.

517: Abe S, Kubota T. [Strategy for patients with GIST after failure of imatinib]. Gan To Kagaku Ryoho. 2009 Apr;36(4):540-3. Japanese. PubMed PMID: 19381023.

518: Richards TM, Plowman PN, Reznek R, Ball SA. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2009 Oct;21(8):633-4. Epub 2009 Apr 19. PubMed PMID: 19380217.

519: Chen MH. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep. 2009 May;11(3):167-74. Review. PubMed PMID: 19379636.

520: Koumbadinga GA, Petitclerc E, Bouthillier J, Adam A, Marceau F. Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle. Eur J Pharmacol. 2009 Mar 15;606(1-3):233-9. Epub 2009 Jan 21. PubMed PMID: 19374866.

521: Trabelsi S, Boussen H, Gaïes E, Salouage I, El Aïdli S, Daghfous R, Loueslati MH, Lakhal M, Belkahia C. [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity]. Therapie. 2008 Nov-Dec;63(6):475-6. French. PubMed PMID: 19374036.

522: Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol. 2009 Apr;4(2):67-76. Epub 2009 Apr 17. Review. PubMed PMID: 19373440.

523: Szmit S, Zagrodzka M, Kurzyna M, Opolski G, Szczylik C. Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma. Cardiology. 2009;114(1):67-71. Epub 2009 Apr 17. PubMed PMID: 19372677.

524: Medioni J, Choueiri TK, Zinzindohoué F, Cho D, Fournier L, Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol. 2009 Jun;181(6):2470-5; discussion 2475. Epub 2009 Apr 16. PubMed PMID: 19371877.

525: Pal SK, Gupta RK, Dosik G, Figlin RA. Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach. Curr Oncol. 2009 Mar;16(2):44-7. PubMed PMID: 19370179; PubMed Central PMCID: PMC2669228.

526: Tahara M, Shibata A, Yamaguchi S, Hamada Y. [Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug]. Nippon Yakurigaku Zasshi. 2009 Apr;133(4):215-26. Review. Japanese. PubMed PMID: 19367024.

527: McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009 May 1;69(9):3937-46. Epub 2009 Apr 14. PubMed PMID: 19366796; PubMed Central PMCID: PMC2676215.

528: Taussky D, Soulières D. Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect? Can J Urol. 2009 Apr;16(2):4599-600. PubMed PMID: 19364436.

529: Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S7-16. Review. PubMed PMID: 19362948.

530: Asemissen AM, Brossart P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother. 2009 Jul;58(7):1169-74. Epub 2009 Apr 10. PubMed PMID: 19360405.

531: Durant C, Saint-Jean M, Connault J, Pistorius MA, Planchon B. [Necrotizing hand-foot skin reaction induced by antiangiogenic in a patient with Thevenard neuroacropathy]. J Mal Vasc. 2009 May;34(3):222-5. Epub 2009 Apr 8. French. PubMed PMID: 19359111.

532: Otto T, Eimer C, Gerullis H. Temsirolimus in renal cell carcinoma. Transplant Proc. 2008 Dec;40(10 Suppl):S36-9. PubMed PMID: 19100905.

533: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. PubMed PMID: 19357798.

534: Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour. Invest New Drugs. 2010 Apr;28(2):199-202. Epub 2009 Apr 8. PubMed PMID: 19352594.

535: Santarpia L, Habra MA, Jiménez C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res. 2009 Sep;41(9):680-6. Epub 2009 Apr 2. Review. PubMed PMID: 19343618.

536: Reeves DJ, Liu CY. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2009 Jun;64(1):11-25. Epub 2009 Apr 3. Review. PubMed PMID: 19343348.

537: Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs. 2009 Jan;20(1):81-2. PubMed PMID: 19343005.

538: Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta. 2009 Jun 27;404(2):134-9. Epub 2009 Mar 31. PubMed PMID: 19341717.

539: NICE celebrates 10th anniversary amid renal cancer drug controversy. BJU Int. 2009 Apr;103(8):ii-iii. PubMed PMID: 19338568.

540: Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A. Targeted therapies in metastatic renal cancer in 2009. BJU Int. 2009 May;103(10):1334-42. Epub 2009 Mar 11. Review. PubMed PMID: 19338565.

541: Gandhi L, McNamara KL, Li D, Borgman CL, McDermott U, Brandstetter KA, Padera RF, Chirieac LR, Settleman JE, Wong KK. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila Pa). 2009 Apr;2(4):330-7. Epub 2009 Mar 31. PubMed PMID: 19336729; PubMed Central PMCID: PMC2696128.

542: Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother. 2009 Apr;43(4):761-6. Epub 2009 Mar 31. PubMed PMID: 19336648.

543: Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep. 2009 May;11(3):244-9. Review. PubMed PMID: 19336017.

544: Courtney KD, Choueiri TK. Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep. 2009 May;11(3):218-26. Review. PubMed PMID: 19336014.

545: Chan JA, Kulke MH. Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep. 2009 May;11(3):193-9. Review. PubMed PMID: 19336011.

546: Nilsson B, Nilsson O, Ahlman H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then? Expert Opin Investig Drugs. 2009 Apr;18(4):457-68. Review. PubMed PMID: 19335275.

547: Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. Review. PubMed PMID: 19333228.

548: Rolleman EJ, Weening J, Betjes MG. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transplant. 2009 Jun;24(6):2002-3. Epub 2009 Mar 30. PubMed PMID: 19332867.

549: Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009 Apr;122(4):322-8. Review. PubMed PMID: 19332223.

550: Chen SY, Kao PC, Lin ZZ, Chiang WC, Fang CC. Sunitinib-induced myxedema coma. Am J Emerg Med. 2009 Mar;27(3):370.e1-370.e3. PubMed PMID: 19328392.

551: Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul;52(7):767-71. PubMed PMID: 19326424.

552: Wong MK, Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy. 2009 Apr;29(4):473-8. Review. PubMed PMID: 19323623.

553: Feyerabend S, Schilling D, Wicke C, Stenzl A. Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to forefoot amputation. Urol Int. 2009;82(2):246-8. Epub 2009 Mar 19. PubMed PMID: 19322019.

554: Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2009;76(5):350-4. Epub 2009 Mar 24. PubMed PMID: 19321976.

555: von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009 Apr 1;69(7):3032-41. Epub 2009 Mar 24. PubMed PMID: 19318574.

556: Stollman TH, Ruers TJ, Oyen WJ, Boerman OC. New targeted probes for radioimaging of angiogenesis. Methods. 2009 Jun;48(2):188-92. Epub 2009 Mar 24. Review. PubMed PMID: 19318127.

557: Ohlmann CH. [Prognostic factors for survival of patients with metastatic renal cell carcinoma]. Urologe A. 2009 Jun;48(6):625-7. Review. German. PubMed PMID: 19300979.

558: Mauri D, Panou C, Valachis A, Kamposioras K, Tsali L. Tyrosine kinase inhibitors in treatment of fibrous histiocytoma. Exp Oncol. 2009 Mar;31(1):60-1. PubMed PMID: 19300420.

559: Taylor M, Geoerger B, Lagodny J, Farace F, Vassal G, Rössler J. [Potential role of antiangiogenic treatment in neuroblastoma]. Arch Pediatr. 2009 May;16(5):457-67. Epub 2009 Mar 18. Review. French. PubMed PMID: 19299115.

560: Dreyer C, Raymond E, Faivre S. [Targeted therapies and their indications in solid neoplasias]. Rev Med Interne. 2009 May;30(5):416-24. Epub 2009 Mar 18. Review. French. PubMed PMID: 19299048.

561: Mizutani Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Int J Urol. 2009 May;16(5):444-8. Epub 2009 Mar 3. Review. PubMed PMID: 19298634.

562: Khosravi Shahi P, Castillo Rueda AD, Pérez Manga G. [Neoplastic angiogenesis]. An Med Interna. 2008 Jul;25(7):366-9. Review. Spanish. PubMed PMID: 19296000.

563: Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2009 Jun;86(3):204-13. PubMed PMID: 19294680.

564: Cameron S, Savvoukidis T, Armbrust T, Haller F, Kitz J, Füzesi L, Ramadori G. Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors. Med Oncol. 2010 Jun;27(2):213-8. Epub 2009 Mar 18. PubMed PMID: 19294538.

565: Khosravi Shahi P, Soria Lovelle A, Pérez Manga G. Tumoral angiogenesis and breast cancer. Clin Transl Oncol. 2009 Mar;11(3):138-42. Review. PubMed PMID: 19293050.

566: Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009 Jan;10(1):28-35. Review. PubMed PMID: 19289369.

567: Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009 Mar;22(1):115-28. Review. PubMed PMID: 19285278.

568: Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009 Mar 12;9:82. PubMed PMID: 19284623; PubMed Central PMCID: PMC2662874.

569: Raut CP, Bertagnolli MM. Controversies in the surgical management of GIST in the era of imatinib. Oncology (Williston Park). 2009 Jan;23(1):69, 74-6. PubMed PMID: 19283924.

570: von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation? Oncology (Williston Park). 2009 Jan;23(1):65-6. PubMed PMID: 19283923; PubMed Central PMCID: PMC2861343.

571: Fernandes Gdos S, Blanke CD, Freitas D, Guedes R, Hoff PM. Perioperative treatment of gastrointestinal stromal tumors. Oncology (Williston Park). 2009 Jan;23(1):54-61. Review. PubMed PMID: 19283922.

572: George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009 Jul;45(11):1959-68. Epub 2009 Mar 11. PubMed PMID: 19282169.

573: Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, Grande-Pulido E, Melero I, Perez-Gracia JL. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009 Apr 7;100(7):1111-9. Epub 2009 Mar 10. PubMed PMID: 19277038; PubMed Central PMCID: PMC2670006.

574: Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009 Mar 15;69(6):2514-22. Epub 2009 Mar 10. PubMed PMID: 19276342.

575: Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009 Mar 15;15(6):2148-57. Epub 2009 Mar 10. PubMed PMID: 19276286.

576: Chowdhury S, Choueiri TK. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther. 2009 Mar;9(3):373-9. Review. PubMed PMID: 19275514.

577: Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, Kim YR, Park TS, Ahn JH, Lee DH, Kim TW, Lee JS. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol. 2009 May;39(5):327-31. Epub 2009 Mar 4. PubMed PMID: 19264767.

578: Bellmunt J, Calvo E, Castellano D, Climent MA, Esteban E, García del Muro X, González-Larriba JL, Maroto P, Trigo JM. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol. 2009 Mar;63 Suppl 1:S1-13. PubMed PMID: 19259675.

579: Jiang Y, Ming L, Montero AJ, Kimchi E, Nikfarjam M, Staveley-O'Carroll KF. Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors. Gastrointest Cancer Res. 2008 Sep;2(5):245-50. PubMed PMID: 19259308; PubMed Central PMCID: PMC2632557.

580: Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009 Apr 1;15(7):2497-506. Epub 2009 Mar 3. PubMed PMID: 19258444.

581: Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009 May;94(5):1493-9. Epub 2009 Mar 3. Review. PubMed PMID: 19258410.

582: Tapiawala SN, Bargman JM, Oreopoulos DG, Simons M. Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates. Int Urol Nephrol. 2009;41(2):431-4. Epub 2009 Mar 3. PubMed PMID: 19255867.

583: Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009 Mar 3;15(3):232-9. PubMed PMID: 19249681.

584: Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev. 2009 May;35(3):297-307. Epub 2009 Feb 26. Review. PubMed PMID: 19249157.

585: Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin North Am. 2009 Feb;23(1):129-37, ix. Review. PubMed PMID: 19248976.

586: Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009 Feb;23(1):97-107, viii-ix. Review. PubMed PMID: 19248973.

587: Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009 Mar 15;69(6):2506-13. Epub 2009 Feb 24. PubMed PMID: 19244102; PubMed Central PMCID: PMC2664264.

588: Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindié E, Moretti JL. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009 Feb;24(1):137-44. PubMed PMID: 19243256.

589: Mignogna MD, Fortuna G, Leuci S, Pollio A, Ruoppo E. Sunitinib adverse event: oral bullous and lichenoid mucositis. Ann Pharmacother. 2009 Mar;43(3):546-7. Epub 2009 Feb 24. PubMed PMID: 19240256.

590: Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009 Feb-Mar;32(2):181-5. PubMed PMID: 19238017.

591: Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol. 2009 Feb 23;2:9. PubMed PMID: 19236713; PubMed Central PMCID: PMC2654905.

592: Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. Epub 2009 Feb 18. PubMed PMID: 19232821.

593: Schmidinger M, Zielinski CC. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treat Rev. 2009 May;35(3):289-96. Epub 2009 Feb 15. Review. PubMed PMID: 19232474.

594: Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Mar 20;27(9):1432-9. Epub 2009 Feb 17. PubMed PMID: 19224847.

595: Soria JC, Massard C, Izzedine H. From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol. 2009 Mar 20;27(9):1359-61. Epub 2009 Feb 17. PubMed PMID: 19224836.

596: Sugiyama T, Kumagai S, Hatayama S. [Treatments of epithelial ovarian cancer by histologic subtype]. Gan To Kagaku Ryoho. 2009 Feb;36(2):187-92. Japanese. PubMed PMID: 19223734.

597: Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009 Feb;2(1):15-25. PubMed PMID: 20376335; PubMed Central PMCID: PMC2849142.

598: Ko JS, Bukowski RM, Fincke JH. Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep. 2009 Mar;11(2):87-93. Review. PubMed PMID: 19216839.

599: Gomez-Abuin G, Karam AA, Mezzadri NA, Bas CA. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer. 2009 Jan;7(1):62-3. PubMed PMID: 19213671.

600: Staehler M, Schöppler G, Haseke N, Stadler T, Karl A, Siebels M, Ihrler S, Stief CG. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer. 2009 Jan;7(1):58-61. PubMed PMID: 19213670.

601: Laber DA, Mushtaq M. Compassionate use of sorafenib in patients with advanced renal cell cancer. Clin Genitourin Cancer. 2009 Jan;7(1):34-8. PubMed PMID: 19213666.

602: Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan;7(1):28-33. PubMed PMID: 19213665.

603: Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan;7(1):24-7. PubMed PMID: 19213664.

604: Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009 Jan;7(1):11-9. PubMed PMID: 19213662.

605: Bukowski RM. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm. Clin Genitourin Cancer. 2009 Jan;7(1):9-10. PubMed PMID: 19213661.

606: Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VW, Broxterman HJ. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis. 2009;12(1):69-79. Epub 2009 Feb 11. PubMed PMID: 19212818.

607: Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009;76(3):209-11. Epub 2009 Feb 12. PubMed PMID: 19212145.

608: Ansari J, Fatima A, Chaudhri S, Bhatt RI, Wallace M, James ND. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie. 2009 Feb;32(1-2):44-6. Epub 2009 Jan 19. PubMed PMID: 19209019.

609: Mayor S. NICE recommends kidney cancer drug it previously rejected on cost grounds. BMJ. 2009 Feb 9;338:b499. doi: 10.1136/bmj.b499. PubMed PMID: 19204038.

610: Hill KL Jr, Lipson AC, Sheehan JM. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J Neurosurg. 2009 Sep;111(3):497-503. PubMed PMID: 19199506.

611: Huang CC, Yang CY, Lai IR, Chen CN, Lee PH, Lin MT. Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg. 2009 Apr;33(4):828-34. PubMed PMID: 19198935.

612: Szmit S, Nurzyński P, Szaluś N, Opolski G, Szczylik C. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2009;48(6):921-5. PubMed PMID: 19191048.

613: Sevinc A. Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report. Chemotherapy. 2009;55(2):132-6. Epub 2009 Feb 3. PubMed PMID: 19188713.

614: van der Veldt AA, Boven E, Vroling L, Broxterman HJ, van den Eertwegh AJ, Haanen JG. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol. 2009 Mar 10;27(8):1339-40; author reply 1340-2. Epub 2009 Feb 2. PubMed PMID: 19188672.

615: Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009 Feb 1;15(3):1096-104. PubMed PMID: 19188185.

616: Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol. 2009 Mar;20(3):600-1. Epub 2009 Feb 2. PubMed PMID: 19188135.

617: Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol. 2009 May;70(2):93-102. Epub 2009 Jan 31. Review. PubMed PMID: 19186072.

618: Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol. 2009 Feb;10(2):157-63. Review. PubMed PMID: 19185833.

619: Bernstein ML. Hits and misses in targeting pediatric cancers. Pediatr Blood Cancer. 2009 Jul;52(7):751-2. PubMed PMID: 19185009.

620: Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. Aktuelle Urol. 2009 Jan;40(1):31-6. Epub 2009 Jan 28. German. PubMed PMID: 19177319.

621: Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U; interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG). [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol. 2009 Jan;40(1):27-30. Epub 2009 Jan 28. German. PubMed PMID: 19177318.

622: Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer. 2009 Jan 27;9:34. Review. PubMed PMID: 19173737; PubMed Central PMCID: PMC2637892.

623: Vogl UM, Berger W, Micksche M, Pirker C, Lamm W, Pichelmeyer O, Zielinski CC, Schmidinger M. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett. 2009 May 18;277(2):218-26. Epub 2009 Jan 25. PubMed PMID: 19171421.

624: Mascitelli L, Goldstein MR, Pezzetta F. Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. Clin Endocrinol (Oxf). 2009 Sep;71(3):455-6; author reply 456-7. Epub 2009 Jan 19. PubMed PMID: 19170713.

625: Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol. 2009 Sep;64(4):691-706. Epub 2009 Jan 25. PubMed PMID: 19169880.

626: Lee JO, Lee KW, Kim CJ, Kim YJ, Lee HE, Kim H, Kim JH, Bang SM, Kim JS, Lee JS. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol. 2009 Mar;39(3):183-5. Epub 2009 Jan 24. PubMed PMID: 19168875.

627: Zastrow S, Froehner M, Platzek I, Novotny V, Wirth MP. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology. 2009 Apr;73(4):868-70. Epub 2009 Jan 23. PubMed PMID: 19167044.

628: Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. Epub 2009 Jan 21. PubMed PMID: 19164557; PubMed Central PMCID: PMC2635778.

629: de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009 Mar;45(5):765-73. Epub 2009 Jan 20. Review. PubMed PMID: 19157861.

630: Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M, Andrieu JM, Oudard S. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. Eur Urol. 2009 Jul;56(1):207-11; quiz 211. Epub 2009 Jan 13. PubMed PMID: 19157688.

631: Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009 Mar;103(5):572-7. Review. PubMed PMID: 19154471.

632: Desar IM, Burger DM, Van Hoesel QG, Beijnen JH, Van Herpen CM, Van der Graaf WT. Pharmacokinetics of sunitinib in an obese patient with a GIST. Ann Oncol. 2009 Mar;20(3):599-600. Epub 2009 Jan 19. PubMed PMID: 19153120.

633: Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009 May;20(5):807-15. Epub 2009 Jan 15. Review. PubMed PMID: 19150949.

634: Robert G, Gabbay G, Bram R, Wallerand H, Deminière C, Cornelis F, Bernhard JC, Ravaud A, Ballanger P. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol. 2009 Jun;55(6):1477-80. Epub 2009 Jan 9. PubMed PMID: 19150171.

635: Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem. 2009 Jan;9(1):66-76. Review. PubMed PMID: 19149483.

636: Biswas S, Kelly J, Eisen T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist. 2009 Jan;14(1):52-9. Epub 2009 Jan 15. Review. PubMed PMID: 19147692.

637: Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009 Aug;27(4):533-9. Epub 2009 Jan 15. PubMed PMID: 19145434.

638: Huynh H, Lee JW, Chow PK, Ngo VC, Lew GB, Lam IW, Ong HS, Chung A, Soo KC. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. PubMed PMID: 19139124.

639: Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol Cancer Ther. 2009 Jan;8(1):55-63. PubMed PMID: 19139113.

640: Daniels GH. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al. Clin Endocrinol (Oxf). 2009 Sep;71(3):455. Epub 2008 Dec 5. PubMed PMID: 19138312.

641: Reckova M, Kakalejcik M, Beniak J. Treatment of hemodialyzed patient with sunitinib. Ann Oncol. 2009 Feb;20(2):392-3. Epub 2009 Jan 8. PubMed PMID: 19136449.

642: Virostko J, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol. 2009 May-Jun;11(3):204-12. Epub 2009 Jan 7. PubMed PMID: 19130143; PubMed Central PMCID: PMC2677126.

643: Fujita Y, Abe R, Shimizu H. Clinical approaches toward tumor angiogenesis: past, present and future. Curr Pharm Des. 2008;14(36):3820-34. Review. PubMed PMID: 19128235.

644: Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI, Kollmannsberger C. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer. 2009 Feb 15;115(4):776-83. PubMed PMID: 19127560.

645: Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int. 2009 Jan;29(1):10-7. Review. PubMed PMID: 19120940.

646: Di Lorenzo G, Scagliarini S, Di Napoli M, Scognamiglio F, Rizzo M, Carteni' G. Targeted therapy in the treatment of metastatic renal cell cancer. Oncology. 2009;77 Suppl 1:122-31. Epub 2010 Feb 2. Review. PubMed PMID: 20130440.

647: Ricciardi S, de Marinis F. New agents in advanced non-small-cell lung cancer treatment. Oncology. 2009;77 Suppl 1:103-12. Epub 2010 Feb 2. Review. PubMed PMID: 20130438.

648: Mansueto G, Longo F. [ASCO 2008. Bevacizumab in advanced renal carcinoma]. Tumori. 2008 Sep-Oct;94(5):15-23. Italian. PubMed PMID: 19112964.

649: Finley DS, Narula N, Valera VA, Merino MJ, Fruehauf J, Wu ML, Linehan WM, Clayman RV. Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: Initial case report. Urol Oncol. 2008 Dec 24. [Epub ahead of print] PubMed PMID: 19110452.

650: Wolter P, Beuselinck B, Pans S, Schöffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol. 2009;48(4):621-4. PubMed PMID: 19107622.

651: Zhu AX, Raymond E. Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2009 Jan;9(1):143-50. Review. PubMed PMID: 19105714.

652: Gridelli C, Maione P, Rossi A, Falanga M, Bareschino M, Schettino C, Colantuoni G, Guerriero C, Nicolella D, Rossi E, Ferrara ML, Palazzolo G. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009 Jan;9(1):115-24. Review. PubMed PMID: 19105711.

653: Czabanka M, Vinci M, Heppner F, Ullrich A, Vajkoczy P. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer. 2009 Mar 15;124(6):1293-300. PubMed PMID: 19101989.

654: Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009 Feb;181(2):518-23; discussion 523. Epub 2008 Dec 18. PubMed PMID: 19100579.

655: Pickering LM, Pyle L, Larkin JM. Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma. Nat Clin Pract Oncol. 2009 Jan;6(1):6-7. PubMed PMID: 19096396.

656: Lee FY, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A, Wen ML, Ryseck RP, Fairchild CR, Fargnoli J, Kramer R. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res. 2008 Dec 15;14(24):8123-31. PubMed PMID: 19088027.

657: Heng DY, Bukowski RM. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets. 2008 Dec;8(8):676-82. Review. PubMed PMID: 19075590.

658: Staehler M, Haseke N, Schöppler G, Stadler T, Karl A, Siebels M, Ihrler S, Stief CG. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. Eur J Med Res. 2008 Nov 24;13(11):531-5. PubMed PMID: 19073390.

659: Méjean A, Lebret T. [Prise en charge of metastatic renal carcinoma]. Prog Urol. 2008 Nov;18 Suppl 7:S298-308. French. PubMed PMID: 19070807.

660: Paz-Ares L, García del Muro X, Grande E, González P, Brosa M, Díaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol. 2008 Dec;10(12):831-9. PubMed PMID: 19068454.

661: Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009 Jan 20;27(3):439-45. Epub 2008 Dec 8. PubMed PMID: 19064982.

662: Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009 Jan 10;27(2):235-41. Epub 2008 Dec 8. PubMed PMID: 19064974.

663: Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol. 2009 Jan 20;27(3):460-3. Epub 2008 Dec 8. PubMed PMID: 19064958.

664: Bajetta E, Guadalupi V, Procopio G. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2009 Jan 10;27(2):319-20; author reply 320. Epub 2008 Dec 8. PubMed PMID: 19064950.

665: Loong HH, Yeo W. Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage. Hong Kong Med J. 2008 Dec;14(6):495-8. PubMed PMID: 19060352.

666: Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noël LH, Knebelmann B. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009 Feb;24(2):682-5. Epub 2008 Dec 2. PubMed PMID: 19054798.

667: Bedke J, Pelzer AE. Words of wisdom. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008 Nov;54(5):1200-1. PubMed PMID: 19051381.

668: Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009 Jan 1;115(1):61-7. PubMed PMID: 19051290.

669: Winn SK, Ellis S, Savage P, Sampson S, Marsh JE. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant. 2009 Feb;24(2):673-5. Epub 2008 Nov 27. PubMed PMID: 19039026.

670: Ashida A, Takata M, Murata H, Kido K, Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer. 2009 Feb 15;124(4):862-8. PubMed PMID: 19035443.

671: Dudek AZ, Nguyen S. Safety of nab-paclitaxel plus sunitinib: analysis of three cases. Anticancer Res. 2008 Sep-Oct;28(5B):3099-105. PubMed PMID: 19031964.

672: Lanzi C, Cassinelli G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol. 2009 Feb 1;77(3):297-309. Epub 2008 Nov 6. PubMed PMID: 19028457.

673: Halimi JM, Azizi M, Bobrie G, Bouché O, Deray G, des Guetz G, Lecomte T, Levy B, Mourad JJ, Nochy D, Oudard S, Rieu P, Sahali D. [Vascular and renal effects of anti-angiogenic therapy]. Nephrol Ther. 2008 Dec;4(7):602-15. Epub 2008 Nov 21. French. PubMed PMID: 19027389.

674: Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009 Jan 13;100(1):19-23. Epub 2008 Nov 18. Review. PubMed PMID: 19018262; PubMed Central PMCID: PMC2634687.

675: Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009 Feb;94(2):386-91. Epub 2008 Nov 18. PubMed PMID: 19017755.

676: Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18895-900. Epub 2008 Nov 17. PubMed PMID: 19015530; PubMed Central PMCID: PMC2596241.

677: Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 2008 Nov;144(11):1525-6. PubMed PMID: 19015436.

678: Margulis V, Wood CG. Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int. 2009 Jan;103(2):150-3. Epub 2008 Nov 4. Review. PubMed PMID: 19007359.

679: Cassier PA, Dufresne A, Arifi S, El Sayadi H, Ray-Coquard I, Bringuier PP, Scoazec JY, Alberti L, Blay JY. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Curr Gastroenterol Rep. 2008 Dec;10(6):555-61. Review. PubMed PMID: 19006610.

680: Park IH, Kwon Y, Kim EA, Lee KS, Ro J. Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast. Invest New Drugs. 2009 Aug;27(4):387-8. Epub 2008 Nov 11. PubMed PMID: 19002383.

681: Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab. 2009 Jan;94(1):5-9. Epub 2008 Nov 11. PubMed PMID: 19001511.

682: Trippoli S, Messori A. Cost effectiveness of sunitinib. J Clin Oncol. 2008 Dec 10;26(35):5829; author reply 5829-30. Epub 2008 Nov 10. PubMed PMID: 19001342.

683: Boone SL, Jameson G, Von Hoff D, Lacouture ME. Blackberry-induced hand-foot skin reaction to sunitinib. Invest New Drugs. 2009 Aug;27(4):389-90. Epub 2008 Nov 8. Erratum in: Invest New Drugs. 2009 Aug;27(4):391. PubMed PMID: 18998055.

684: Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am. 2008 Nov;35(4):687-701; ix. Review. PubMed PMID: 18992622.

685: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PubMed PMID: 18985183.

686: Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S, Bengzon J. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther. 2009 Jan;17(1):183-90. Epub 2008 Nov 4. PubMed PMID: 18985030; PubMed Central PMCID: PMC2834971.

687: Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol. 2008;36(7):905-16. Epub 2008 Nov 3. PubMed PMID: 18981453.

688: Hird AE, Chow E, Ehrlich L, Probyn L, Sinclair E, Yip D, Ko YJ. Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature. J Palliat Med. 2008 Oct;11(8):1156-61. PubMed PMID: 18980461.

689: Melgar-Lesmes P, Tugues S, Ros J, Fernández-Varo G, Morales-Ruiz M, Rodés J, Jiménez W. Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats. Gut. 2009 Feb;58(2):285-92. Epub 2008 Oct 31. PubMed PMID: 18978178.

690: Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol. 2009 Jun;11(3):301-10. Epub 2008 Oct 29. PubMed PMID: 18971416; PubMed Central PMCID: PMC2718974.

691: Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. Epub 2008 Oct 29. PubMed PMID: 18971320; PubMed Central PMCID: PMC2680522.

692: Lattarulo S, Di Gennaro F, Borrello G, Lospalluti M, Fabiano G, Pezzolla A, Palasciano N. [Laparoscopic treatment of GISTs in our experience]. Ann Ital Chir. 2008 May-Jun;79(3):171-7. Italian. PubMed PMID: 18958964.

693: Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 20;26(33):5352-9. Epub 2008 Oct 27. PubMed PMID: 18955458; PubMed Central PMCID: PMC2651076.

694: Judson IR. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype. J Clin Oncol. 2008 Nov 20;26(33):5322-5. Epub 2008 Oct 27. PubMed PMID: 18955449.

695: Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol. 2009 Jun;55(6):1430-8. Epub 2008 Oct 18. PubMed PMID: 18950936.

696: Bamias A. Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol. 2009 Jun;55(6):1439. Epub 2008 Oct 18. PubMed PMID: 18950935.

697: Bórquez Ma P, Neveu C R. [Gastrointestinal stromal tumors. An update]. Rev Med Chil. 2008 Jul;136(7):921-9. Epub 2008 Sep 4. Review. Spanish. PubMed PMID: 18949171.

698: Wells RJ. The sex kitten of bioethics? Research ethics comes of age. Hastings Cent Rep. 2008 Sep-Oct;38(5):6-7; author reply 7. PubMed PMID: 18947128.

699: Hur H, Park AR, Jee SB, Jung SE, Kim W, Jeon HM. Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. World J Gastroenterol. 2008 Oct 21;14(39):6096-9. PubMed PMID: 18932293; PubMed Central PMCID: PMC2760196.

700: Penel N, Adenis A. Publication biases and phase II trials investigating anticancer targeted therapies. Invest New Drugs. 2009 Jun;27(3):287-8. Epub 2008 Oct 18. PubMed PMID: 18931825.

701: Matsumoto K, Saida T. [Cutaneous toxicities]. Gan To Kagaku Ryoho. 2008 Oct;35(10):1645-8. Japanese. PubMed PMID: 18931563.

702: Nishida T. [Contemporary treatment of gastrointestinal stromal tumors]. Gan To Kagaku Ryoho. 2008 Oct;35(10):1639-44. Review. Japanese. PubMed PMID: 18931562.

703: Hutson TE. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2008 Nov;8(11):1723-31. Review. PubMed PMID: 18928373.

704: Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008 Oct 15;14(20):6674-82. PubMed PMID: 18927310.

705: Hutson TE, Figlin RA. Experimental therapy for advanced renal cell carcinoma. Expert Opin Investig Drugs. 2008 Nov;17(11):1693-702. Review. PubMed PMID: 18922106.

706: Daher IN, Yeh ET. Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med. 2008 Dec;5(12):797-805. Epub 2008 Oct 14. Review. PubMed PMID: 18852710.

707: Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone. 2009 Jan;44(1):173-5. Epub 2008 Sep 24. PubMed PMID: 18849018.

708: Billemont B, Medioni J, Taillade L, Helley D, Meric JB, Rixe O, Oudard S. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2008 Nov 4;99(9):1380-2. Epub 2008 Oct 7. PubMed PMID: 18841151; PubMed Central PMCID: PMC2579676.

709: Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008 Nov 10;26(32):5204-12. Epub 2008 Oct 6. PubMed PMID: 18838713.

710: Lenihan DJ. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol. 2008 Nov 10;26(32):5154-5. Epub 2008 Oct 6. PubMed PMID: 18838702.

711: Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008 Oct;13(10):1084-96. Epub 2008 Oct 6. Review. PubMed PMID: 18838439.

712: Escudier B. Signaling inhibitors in metastatic renal cell carcinoma. Cancer J. 2008 Sep-Oct;14(5):325-9. PubMed PMID: 18836338.

713: Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol. 2009 Feb;33(2):218-26. PubMed PMID: 18830121.

714: Sire M, Wallerand H, Kilkoski F, Grenier N, Ferrière JM, Ravaud A. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma]. Bull Cancer. 2008 Sep;95(9):813-20. French. PubMed PMID: 18829413.

715: Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer. 2008 Oct;44(15):2152-61. Epub 2008 Sep 29. Review. PubMed PMID: 18829302.

716: Maitland ML. Cardiovascular toxicity of new agents. Clin Adv Hematol Oncol. 2008 Sep;6(9):657-9. PubMed PMID: 18827788.

717: Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol. 2008 Oct;3(10):1173-84. Review. PubMed PMID: 18827616.

718: Staehler M, Haseke N, Zilinberg K, Stadler T, Karl A, Stief CG. [Systemic therapy of metastasizing renal cell carcinoma]. Urologe A. 2008 Oct;47(10):1357-67. German. PubMed PMID: 18825295.

719: Garfield DH, Wolter P, Schöffski P, Hercbergs A, Davis P. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? J Clin Oncol. 2008 Nov 1;26(31):5131-2; author reply 5132-3. Epub 2008 Sep 29. PubMed PMID: 18824699.

720: Sonpavde G, Hutson TE, Berry WR, Boehm KA, Asmar L. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer. 2008 Sep;6(2):134-7. PubMed PMID: 18824440.

721: Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer. 2008 Sep;6(2):122-3. PubMed PMID: 18824436.

722: Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H, Baker SD. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 15;874(1-2):84-8. Epub 2008 Sep 12. PubMed PMID: 18823825; PubMed Central PMCID: PMC2612784.

723: Elice F, Jacoub J, Rickles FR, Falanga A, Rodeghiero F. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol. 2008 Nov;83(11):862-70. Review. PubMed PMID: 18819092.

724: Hasinoff BB, Patel D, O'Hara KA. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol. 2008 Dec;74(6):1722-8. Epub 2008 Sep 24. PubMed PMID: 18815214.

725: Oudard S, Cornu JN, Rouprêt M, Patard JJ. [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives]. Prog Urol. 2008 Jul;18 Suppl 4:S77-80. French. PubMed PMID: 18706375.

726: Cornu JN, Rouprêt M, Bensalah K, Oudard S, Patard JJ. [Antiangiogenics: new therapeutic standards in metastatic kidney cancer]. Prog Urol. 2008 Jul;18 Suppl 4:S69-76. French. PubMed PMID: 18706374.

727: Vakkalanka BK, Bukowski RM. Novel drugs for renal cell carcinoma. Expert Opin Investig Drugs. 2008 Oct;17(10):1501-16. Review. PubMed PMID: 18808310.

728: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408. PubMed PMID: 18806898.

729: Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol. 2009 Jan;55(1):237-9; quiz 239. Epub 2008 Sep 17. PubMed PMID: 18804907.

730: Izzedine H, Etienne-Grimaldi MC, Renée N, Vignot S, Milano G. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol. 2009 Jan;20(1):190-2. Epub 2008 Sep 18. PubMed PMID: 18801884.

731: Maluf FC, Fernandes Gdos S, Kann AG, Aguilar-Ponce JL, de la Garza J, Buzaid AC. Exploring the role of novel agents in the treatment of renal cell carcinoma. Cancer Treat Rev. 2008 Dec;34(8):750-60. Epub 2008 Sep 17. Review. PubMed PMID: 18801619.

732: Kakehi Y. [Molecular targeted therapy for renal cell carcinoma]. Rinsho Ketsueki. 2008 Aug;49(8):622-5. Review. Japanese. PubMed PMID: 18800611.

733: Obara W, Fujioka T. [Renal cell carcinoma]. Gan To Kagaku Ryoho. 2008 Sep;35(9):1482-7. Japanese. PubMed PMID: 18799901.

734: Hamaoka T. [New period of systemic treatment for breast cancer]. Gan To Kagaku Ryoho. 2008 Sep;35(9):1457-60. Japanese. PubMed PMID: 18799897.

735: van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res. 2008 Sep 15;14(18):5884-92. PubMed PMID: 18794101.

736: Weisenthal LM, Patel N, Rueff-Weisenthal C. Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood. J Intern Med. 2008 Sep;264(3):275-87. PubMed PMID: 18793333.

737: Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. Epub 2008 Sep 12. PubMed PMID: 18791128.

738: Kahl C, Hilgendorf I, Freund M, Casper J. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma. Onkologie. 2008 Sep;31(8-9):485. Epub 2008 Jul 31. PubMed PMID: 18787358.

739: Harshman L, Srinivas S. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. Onkologie. 2008 Sep;31(8-9):432-3. Epub 2008 Aug 12. PubMed PMID: 18787349.

740: Kruck S, Kuczyk MA, Gakis G, Kramer MW, Stenzl A, Merseburger AS. Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update. Rev Recent Clin Trials. 2008 Sep;3(3):212-6. Review. PubMed PMID: 18782079.

741: Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. Epub 2008 Sep 8. Review. PubMed PMID: 18779536.

742: Reichardt P. Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep. 2008 Jul;10(4):344-9. Review. PubMed PMID: 18778561.

743: Rini BI, Flaherty K. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol. 2008 Sep-Oct;26(5):543-9. Review. PubMed PMID: 18774471.

744: Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72. Epub 2008 Sep 5. Review. PubMed PMID: 18774306.

745: Pföhler C, Ugurel S. [Cutaneous reactions to molecular targeted therapies]. Hautarzt. 2008 Oct;59(10):814-20. Review. German. PubMed PMID: 18766322.

746: Flaherty KT. The future of tyrosine kinase inhibitors: single agent or combination? Curr Oncol Rep. 2008 May;10(3):264-70. Review. PubMed PMID: 18765158.

747: Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep. 2008 May;10(3):199-205. Review. PubMed PMID: 18765149.

748: Billemont B, Barete S, Rixe O. Scrotal cutaneous side effects of sunitinib. N Engl J Med. 2008 Aug 28;359(9):975-6; discussion 976. PubMed PMID: 18753659.

749: Vetter ML, Kaul S, Iqbal N. Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. Endocr Pract. 2008 Jul-Aug;14(5):618-24. Review. PubMed PMID: 18753108.

750: Prenen H, Gil T, Awada A. New therapeutic developments in renal cell cancer. Crit Rev Oncol Hematol. 2009 Jan;69(1):56-63. Epub 2008 Aug 26. Review. PubMed PMID: 18752971.

751: Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9-17. Review. PubMed PMID: 18752081.

752: Moch H. [Molecular basis of targeted therapy in metastatic renal cancer]. Pathologe. 2008 Nov;29 Suppl 2:184-6. Review. German. PubMed PMID: 18751979.

753: Tuma RS. Major treatment improvements encourage kidney cancer researchers to seek further gains. J Natl Cancer Inst. 2008 Sep 3;100(17):1202-3. Epub 2008 Aug 26. PubMed PMID: 18728277.

754: Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol. 2008 Nov;19(11):1975. Epub 2008 Aug 22. PubMed PMID: 18723549.

755: Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Clohisy DR, Dudek AZ. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer. 2008 Nov;44(16):2506-17. Epub 2008 Aug 22. PubMed PMID: 18723339.

756: Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008 Oct 1;113(7):1552-8. PubMed PMID: 18720362.

757: Taran A, Ignatov A, Smith B, Costa SD, Bischoff J. Acute hepatic failure following monotherapy with sunitinib for ovarian cancer. Cancer Chemother Pharmacol. 2009 Apr;63(5):971-2. Epub 2008 Aug 21. PubMed PMID: 18716778.

758: Herrmann E, Bierer S, Gerss J, Köpke T, Hertle L, Wülfing C. Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology. 2008;74(3-4):216-22. Epub 2008 Aug 20. PubMed PMID: 18714170.

759: Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol. 2008 Aug 20;26(24):4047-8. PubMed PMID: 18711201.

760: Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 20;26(24):3995-4000. PubMed PMID: 18711190.

761: Guenova E, Weber HO, Voykov B, Metzler G, Mitev V, Berneburg M, Hoetzenecker W, Röcken M. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease. Arch Dermatol. 2008 Aug;144(8):1081-2. PubMed PMID: 18711102.

762: Obhrai JS, Patel TV, Humphreys BD. The case / progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int. 2008 Sep;74(5):685-6. PubMed PMID: 18709027.

763: Bierer S, Hertle L, Nitschmann S. [New therapeutic regimes in metastasic renal-cell carcinoma]. Internist (Berl). 2008 Jan;49(1):114-7. German. PubMed PMID: 18704353.

764: O'Dowd A. Watchdog set to reject four drugs for kidney cancer on the NHS. BMJ. 2008 Aug 14;337:a1262. doi: 10.1136/bmj.a1262. PubMed PMID: 18703648.

765: Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008 Dec;54(6):1373-8. Epub 2008 Aug 8. PubMed PMID: 18692304.

766: Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008 May;3(2):132-43. Review. PubMed PMID: 18690886.

767: Braconi C, Bracci R, Cellerino R. Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets. 2008 Aug;8(5):359-66. Review. PubMed PMID: 18690842.

768: Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets. 2008 Aug;8(5):349-58. Review. PubMed PMID: 18690841.

769: Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care. 2008 Sep;2(3):161-6. Review. PubMed PMID: 18685415.

770: Patard JJ, Pouessel D, Culine S. New therapies in renal cell carcinoma. Curr Opin Support Palliat Care. 2007 Oct;1(3):174-9. Review. PubMed PMID: 18685359.

771: Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology. 2008 Oct;72(4):864-8. Epub 2008 Aug 5. PubMed PMID: 18684493.

772: Rübben H. [Targeted therapy - point blank or single shot]. Urologe A. 2008 Oct;47(10):1297. German. PubMed PMID: 18682912.

773: Vakkalanka BK, Rini BI. Targeted therapy in renal cell carcinoma. Curr Opin Urol. 2008 Sep;18(5):481-7. Review. PubMed PMID: 18670271.

774: Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008 Aug 1;26(22):3763-9. PubMed PMID: 18669464.

775: Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 1;26(22):3743-8. PubMed PMID: 18669461.

776: Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008 Aug 5;99(3):448-54. PubMed PMID: 18665181; PubMed Central PMCID: PMC2527784.

777: Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008 Nov;106(1):153-61. Epub 2008 Jul 29. PubMed PMID: 18664550.

778: Mueller EW, Rockey ML, Rashkin MC. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy. 2008 Aug;28(8):1066-70. PubMed PMID: 18657022.

779: Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56. Epub 2008 Jul 22. PubMed PMID: 18653228.

780: Cao R, Jensen LD, Söll I, Hauptmann G, Cao Y. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One. 2008 Jul 23;3(7):e2748. PubMed PMID: 18648503; PubMed Central PMCID: PMC2447178.

781: Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008 Sep;180(3):860-5; discussion 865-6. Epub 2008 Jul 17. PubMed PMID: 18635227.

782: Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid. 2008 Jul;18(7):809-12. PubMed PMID: 18631016.

783: Sarmiento R, Bonginelli P, Cacciamani F, Salerno F, Gasparini G. Gastrointestinal stromal tumors (GISTs): from science to targeted therapy. Int J Biol Markers. 2008 Apr-Jun;23(2):96-110. Review. PubMed PMID: 18629782.

784: Lu CC, Lin HF, Feng CC, Yu CY, Kao WY. Sunitinib malate as the salvage therapy in advanced rectal carcinoid tumor. Int J Colorectal Dis. 2008 Dec;23(12):1265-6. Epub 2008 Jul 16. PubMed PMID: 18629516.

785: Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008 Sep;216(1):64-74. PubMed PMID: 18623623; PubMed Central PMCID: PMC2693040.

786: Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R, Bukowski RM. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer. 2008 Sep 15;113(6):1309-14. PubMed PMID: 18618496.

787: Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA. An update on the medical therapy of advanced metastatic renal cell carcinoma. Scand J Urol Nephrol. 2008;42(6):501-6. Review. PubMed PMID: 18615363.

788: Strumberg D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J Clin Oncol. 2008 Jul 10;26(20):3469-71; author reply 2471. PubMed PMID: 18612169.

789: Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10;26(20):3403-10. PubMed PMID: 18612155.

790: Mego M, Sycova-Mila Z, Rejlekova K, Rychly B, Obertova J, Rajec J, Hes O, Mardiak J. Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report. Ann Oncol. 2008 Sep;19(9):1655-6. Epub 2008 Jul 8. PubMed PMID: 18611864.

791: Trinkaus M, Trudeau M, Callum J. Drug-induced immune thrombocytopenic purpura secondary to sunitinib. Curr Oncol. 2008 Jun;15(3):152-4. PubMed PMID: 18596889; PubMed Central PMCID: PMC2442762.

792: van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008 Jul 22;99(2):259-65. Epub 2008 Jul 1. PubMed PMID: 18594533; PubMed Central PMCID: PMC2480961.

793: Herrmann E, Gerss J, Bierer S, Köpke T, Bolenz C, Hertle L, Wülfing C. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol. 2009 Jan;135(1):61-7. Epub 2008 Jul 1. PubMed PMID: 18592270.

794: Moldawer NP, Figlin R. Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. Oncol Nurs Forum. 2008 Jul;35(4):699-708. Review. PubMed PMID: 18591174.

795: Merseburger AS, Kuczyk MA. [Value of targeted therapies for renal cell cancer]. Urologe A. 2008 Oct;47(10):1303-10. Review. German. PubMed PMID: 18587556.

796: Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, Iacobelli S. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett. 2008 Nov 8;270(2):229-33. Epub 2008 Jun 30. PubMed PMID: 18586384.

797: Salem AK, Fenton MS, Marion KM, Hershman JM. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid. 2008 Jun;18(6):631-5. PubMed PMID: 18578612.

798: Socinski MA. The current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S119-23. Review. PubMed PMID: 18520293.

799: Navid F, Christensen R, Minkin P, Stewart CF, Furman WL, Baker S. Stability of sunitinib in oral suspension. Ann Pharmacother. 2008 Jul;42(7):962-6. Epub 2008 Jun 24. PubMed PMID: 18577759.

800: Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):605-7. Epub 2008 May 21. PubMed PMID: 18565360.

801: Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009 Feb;27(1):83-7. Epub 2008 Jun 18. PubMed PMID: 18563296.

802: Moral MA, Tomillero A. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):149-71. PubMed PMID: 18560631.

803: Sessa C, Guibal A, Del Conte G, Rüegg C; Medscape. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol. 2008 Jul;5(7):378-91. Epub 2008 Jun 17. Review. PubMed PMID: 18560389.

804: Kountourakis P, Kandylis K, Daskalopoulou D, Rigatos G. Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review. J BUON. 2008 Apr-Jun;13(2):281-3. PubMed PMID: 18555479.

805: Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008 Nov;19(11):1955-61. Epub 2008 Jun 10. PubMed PMID: 18550575.

806: Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008 Jun;35(3):274-85. Review. PubMed PMID: 18544442.

807: Klotz L. Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists. Can Urol Assoc J. 2007 Jun;1(2 Suppl):S69-70. PubMed PMID: 18542788; PubMed Central PMCID: PMC2422950.

808: Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J. 2007 Jun;1(2 Suppl):S41-54. PubMed PMID: 18542784; PubMed Central PMCID: PMC2422945.

809: Hotte SJ, Kapoor AK. Systemic therapy for patients with advanced, unresectable ormetastatic renal cell carcinoma: moving to guidelines. Can Urol Assoc J. 2007 Jun;1(2 Suppl):S34-40. PubMed PMID: 18542783; PubMed Central PMCID: PMC2422947.

810: Nahleh ZA. Molecularly targeted therapy in breast cancer: the new generation. Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):100-4. Review. PubMed PMID: 18537752.

811: Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):88-99. Review. PubMed PMID: 18537751.

812: Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009 Jul-Aug;27(4):391-9. Epub 2008 Jun 4. PubMed PMID: 18534874.

813: von Mehren M. The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors. Curr Opin Oncol. 2008 Jul;20(4):428-32. Review. PubMed PMID: 18525339.

814: Amato RJ, Malya R, Rawat A. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. Am J Clin Oncol. 2008 Jun;31(3):237-43. PubMed PMID: 18525301.

815: Akamatsu S, Kanamaru S, Takenawa J, Soeda A. Severe gastrointestinal hemorrhage due to metastatic renal cell carcinoma to the pancreas successfully controlled by transarterial embolization and adjuvant administration of Sunitinib Malate. Hinyokika Kiyo. 2008 Apr;54(4):277-80. PubMed PMID: 18516920.

816: Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Targeted therapy of renal cell cancer. Curr Opin Investig Drugs. 2008 Jun;9(6):570-5. Review. PubMed PMID: 18516756.

817: Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):873-9. PubMed PMID: 18514780.

818: Hueman MT, Schulick RD. Management of gastrointestinal stromal tumors. Surg Clin North Am. 2008 Jun;88(3):599-614, vii. Review. PubMed PMID: 18514701.

819: Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma. N Engl J Med. 2008 May 29;358(22):2389-96. PubMed PMID: 18509125.

820: Gridelli C, Rossi A, Maione P, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Palazzolo G, Falanga M, Colantuoni G. New insights in drug development for the non-small cell lung cancer therapy. Front Biosci. 2008 May 1;13:5108-19. Review. PubMed PMID: 18508573.

821: Gettinger S. Targeted therapy in advanced non-small-cell lung cancer. Semin Respir Crit Care Med. 2008 Jun;29(3):291-301. Review. PubMed PMID: 18506667.

822: Contreras-Hernández I, Mould-Quevedo JF, Silva A, Salinas-Escudero G, Villasís-Keever MA, Granados-García V, Dávila-Loaiza G, Petersen JA, Garduño-Espinosa J. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. Br J Cancer. 2008 Jun 3;98(11):1762-8. Epub 2008 May 27. PubMed PMID: 18506179; PubMed Central PMCID: PMC2410103.

823: Prat A, Serrano C, Valverde C, Calvo E. Acute severe hypothyroidism induced by sunitinib. Radiother Oncol. 2008 Oct;89(1):124-5. Epub 2008 May 24. PubMed PMID: 18502526.

824: Thibault F, Rixe O, Meric JB, Renard-Penna R, Boostan H, Mozer P, Comperat E, Richard F, Bitker MO. [Neoadjuvant therapy for renal cancer.]. Prog Urol. 2008 Apr;18(4):256-8. Epub 2008 May 2. French. PubMed PMID: 18501308.

825: Anagnostou VK, Tiniakos DG, Chorti M, Kiagia M, Tourkantonis I, Alamara C, Syrigos KN. Right sited renal cell carcinoma metastasizing to the contralateral ovary: case report and review of the literature. Pathol Oncol Res. 2009 Mar;15(1):123-7. Epub 2008 May 21. PubMed PMID: 18493874.

826: Ewer MS, Lenihan DJ, Khakoo AY. Sunitinib-related cardiotoxicity: an interdisciplinary issue. Nat Clin Pract Cardiovasc Med. 2008 Jul;5(7):364-5. Epub 2008 May 20. PubMed PMID: 18490940.

827: ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008 Jul;159(1):242-3. Epub 2008 Jul 1. PubMed PMID: 18489600.

828: Doi T. [GIST]. Gan To Kagaku Ryoho. 2008 May;35(5):737-9. Review. Japanese. PubMed PMID: 18487909.

829: Staehler M. Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-8. Eur Urol. 2008 Oct;54(4):950-1; author reply 951-3. Epub 2008 May 9. PubMed PMID: 18486309.

830: Ravaud A, Wallerand H, Culine S, Bernhard JC, Fergelot P, Bensalah K, Patard JJ. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol. 2008 Aug;54(2):315-25. Epub 2008 May 5. Review. PubMed PMID: 18485581.

831: Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul;180(1):94-8. Epub 2008 May 15. PubMed PMID: 18485389.

832: Shuch B, Belldegrun A. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008 May;53(5):1085-6. PubMed PMID: 18485320.

833: Fischer B, Buhl R. [Lung cancer]. Med Klin (Munich). 2008 May 15;103(5):311-20. Review. German. PubMed PMID: 18484217.

834: Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008 May 15;14(10):3204-15. PubMed PMID: 18483389.

835: Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GV, Rubnitz J, Baker SD. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther. 2008 May;7(5):1110-20. PubMed PMID: 18483300.

836: Nakamura M, Miyachi Y. Sunitinib-induced subungual splinter haemorrhage and acral erythema. Eur J Dermatol. 2008 May-Jun;18(3):344-5. Epub 2008 May 13. PubMed PMID: 18474471.

837: Sciarra A, Gentile V, Salciccia S, Alfarone A, Di Silverio F. New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials. 2008 May;3(2):97-103. Review. PubMed PMID: 18474019.

838: Lee CB, Socinski MA. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Rev Recent Clin Trials. 2007 May;2(2):117-20. Review. PubMed PMID: 18473996.

839: Bussolati B, Satolli MA, Camussi G. [The role of angiogenesis in renal carcinoma]. G Ital Nefrol. 2008 May-Jun;25(3):297-305. Review. Italian. PubMed PMID: 18473301.

840: Rini BI, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Oncology (Williston Park). 2008 Apr 15;22(4):388-96; discussion 396, 402-3, 476 passim. Review. PubMed PMID: 18472614.

841: Lièvre A, Landi B, Mitry E, Taïeb J. [Antiangiogenic agents and gastrointestinal cancers]. Gastroenterol Clin Biol. 2008 May;32(5 Pt 1):504-20. Epub 2008 May 8. French. PubMed PMID: 18472378.

842: Sonpavde G, Hutson TE, Rini BI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs. 2008 May;17(5):741-8. Review. Erratum in: Expert Opin Investig Drugs. 2008 Sep;17(9):1405. PubMed PMID: 18447599.

843: Chakŭrov S. [Current progress and problems in oncourology]. Khirurgiia (Sofiia). 2007;(3):54-9. Review. Bulgarian. PubMed PMID: 18437112.

844: Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008 Sep;19(9):1613-8. Epub 2008 Apr 23. PubMed PMID: 18436521.

845: Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006017. Review. PubMed PMID: 18425931.

846: Jia K, Li J. [Anti-angiogenesis targeting drugs: a review]. Ai Zheng. 2008 Apr;27(4):442-6. Review. Chinese. PubMed PMID: 18423135.

847: Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, Rischin D. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs. 2008 Jun;19(5):547-52. PubMed PMID: 18418222.

848: van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008 Apr 15;14(8):2431-6. PubMed PMID: 18413834.

849: Off-label uses of sorafenib and sunitinib. Technol Eval Cent Asses Program Exec Summ. 2008 Feb;22(11):1-4. PubMed PMID: 18411502.

850: Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008 Sep;102(6):692-6. Epub 2008 Apr 10. PubMed PMID: 18410444.

851: Samlowski WE, Wong B, Vogelzang NJ. Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on. BJU Int. 2008 Jul;102(2):162-5. Epub 2008 Jul 1. Review. PubMed PMID: 18410430.

852: Stein E, Aranha O, Agulnik M. New therapeutic options in gastrointestinal stromal tumors. Oncology (Williston Park). 2008 Feb;22(2):206-11; discussion 215-6, 219. Review. PubMed PMID: 18409663.

853: Hariharan S, Lowry S. Cardiotoxicity associated with sunitinib. Lancet. 2008 Apr 12;371(9620):1244-5; author reply 1245. PubMed PMID: 18406854.

854: Kavsak PA, Hotte S. Cardiotoxicity associated with sunitinib. Lancet. 2008 Apr 12;371(9620):1244; author reply 1245. PubMed PMID: 18406853.

855: Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008 Apr;15(2):3954-66. Review. PubMed PMID: 18405442.

856: [Consensus on the medical treatment of gastrointestinal stromal tumors]. Zhonghua Zhong Liu Za Zhi. 2007 Nov;29(11):875-7. Chinese. PubMed PMID: 18396652.

857: Pinthus J. Editorial comment on: Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol. 2009 Feb;55(2):450-1. Epub 2008 Mar 11. PubMed PMID: 18395329.

858: Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. Epub 2008 Apr 3. PubMed PMID: 18394019.

859: Apice G, Milano A, Bruni GS, Iaffaioli RV, Caponigro F. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. Rev Recent Clin Trials. 2006 Jan;1(1):35-42. Review. PubMed PMID: 18393778.

860: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PubMed PMID: 18389098.

861: Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J 2nd, Champion JC, Durand JB, Lenihan DJ. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008 Jun;112(11):2500-8. PubMed PMID: 18386829.

862: Meeks JJ, Kasper KA, Yang X, Kuzel TM, Smith ND. Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor. Urology. 2009 Feb;73(2):444.e11-2. Epub 2008 Apr 2. PubMed PMID: 18384863.

863: Trigo JM, Bellmunt J. [Current strategies in the treatment of renal-cell cancer: targeted therapies]. Med Clin (Barc). 2008 Mar 22;130(10):380-92. Review. Spanish. PubMed PMID: 18381031.

864: de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Review. Dutch. PubMed PMID: 18380383.

865: Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med. 2008 Apr 1;148(7):567. PubMed PMID: 18378960.

866: Kim S, Lee S, Greene AK, Arsenault DA, Le H, Meisel J, Novak K, Flynn E, Heymach JV, Puder M. Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. J Surg Res. 2008 Sep;149(1):115-9. Epub 2007 Nov 21. PubMed PMID: 18374947.

867: Deslandres M, Sibaud V, Chevreau C, Delord JP. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. Ann Dermatol Venereol. 2008 Jan;Spec No 1:16-24. Review. French. PubMed PMID: 18342113.

868: Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer. 2008 May;44(7):972-7. Epub 2008 Mar 26. PubMed PMID: 18372169.

869: Sosman JA. Improving outcomes in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2008 Mar;8(3):481-90. Review. Erratum in: Expert Rev Anticancer Ther. 2008 Dec;8(12):1993-4. PubMed PMID: 18366295.

870: Fenner MH, Beutel G, Grünwald V. Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs. 2008 Apr;17(4):511-22. Review. PubMed PMID: 18363516.

871: Bellersen L. [New drugs; sunitinib and sorafenib]. Ned Tijdschr Geneeskd. 2008 Feb 23;152(8):469-70; author reply 470. Dutch. PubMed PMID: 18363211.

872: Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 2007 Jun;3(2):341-8. PubMed PMID: 18360643; PubMed Central PMCID: PMC1936316.

873: Dong XC, Zhou FS, Zheng JB, Wen R. [Synthesis of 1-furfuryl-indolin-2-one derivatives and preliminary evaluation of their antitumor activities]. Yao Xue Xue Bao. 2008 Jan;43(1):54-9. Chinese. PubMed PMID: 18357732.

874: Nguyen S, Franklin M, Dudek AZ. Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. Transl Res. 2008 Apr;151(4):194-6. Epub 2008 Feb 6. PubMed PMID: 18355766.

875: Hall PS, Kancherla K, Sastry PS, Brown JE. Severe epistaxis with tyrosine kinase inhibitors. Clin Oncol (R Coll Radiol). 2008 May;20(4):318-9. Epub 2008 Mar 18. PubMed PMID: 18353621.

876: Arnaud L, Schartz NE, Bousquet G, Sarandi F, Verola O, Madelaine I, Kerob D, Lebbe C. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma. J Clin Oncol. 2008 Mar 20;26(9):1569-71. Erratum in: J Clin Oncol. 2008 May 20;26(15):2604. PubMed PMID: 18349416.

877: Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10;26(11):1810-6. Epub 2008 Mar 17. PubMed PMID: 18347007.

878: Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther. 2008 Feb;30(2):382-92. PubMed PMID: 18343276.

879: Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008 Apr;58(4):545-70. Review. PubMed PMID: 18342708.

880: Autier J, Mateus C, Wechsler J, Spatz A, Robert C. [Cutaneous side effects of sorafenib and sunitinib]. Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. Epub 2008 Feb 13. Review. French. PubMed PMID: 18342102.

881: Bonnet S, Gaujoux S, Leconte M, Thillois JM, Tissier F, Dousset B. Laparoscopic adrenalectomy for metachronous metastasis from renal cell carcinoma. World J Surg. 2008 Aug;32(8):1809-14. PubMed PMID: 18330621.

882: Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008 Apr;19(4):824-5. Epub 2008 Mar 6. PubMed PMID: 18326519.

883: Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S24-34. Review. PubMed PMID: 18282363.

884: Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008 Mar 1;14(5):1540-9. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308-9. PubMed PMID: 18316579.

885: Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008 May;34(3):193-205. Epub 2008 Mar 4. Review. PubMed PMID: 18313224.

886: Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008 Sep;53(3):245-66. Epub 2008 Feb 28. Review. PubMed PMID: 18312355.

887: Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008 Jun 15;111(12):5610-20. Epub 2008 Feb 29. PubMed PMID: 18310500.

888: Coppin C. Sunitinib for advanced renal cell cancer. Biologics. 2008 Mar;2(1):97-105. PubMed PMID: 19707433; PubMed Central PMCID: PMC2727778.

889: Ivanyi P, Winkler T, Ganser A, Reuter C, Grünwald V. Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int. 2008 Mar;105(13):232-7. Epub 2008 Mar 28. PubMed PMID: 19629201; PubMed Central PMCID: PMC2696772.

890: Perdonà S, Di Trolio R, Di Lorenzo G, Autorino R. A case of renal melanoma metastasis: description of clinico-pathological features. Arch Ital Urol Androl. 2007 Dec;79(4):161-3. PubMed PMID: 18303733.

891: Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):42-8. PubMed PMID: 18293383.

892: Ruka W, Rutkowski P, Szawłowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, Dziewirski W, Siedlecki JA, Michej W. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol. 2009 Jan;35(1):87-91. Epub 2008 Mar 4. PubMed PMID: 18289826.

893: Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008;15(5):422-32. Review. PubMed PMID: 18288997.

894: Banzo I, Quirce R, Martinez-Rodriguez I, Jimenez-Bonilla J, Sainz-Esteban A, Barragan J, Portilla-Quattrociocchi H, Carril JM. F-18 FDG PET/CT assessment of gastrointestinal stromal tumor response to sunitinib malate therapy. Clin Nucl Med. 2008 Mar;33(3):211-2. PubMed PMID: 18287850.

895: O'Brien MF, Russo P, Motzer RJ. Sunitinib therapy in renal cell carcinoma. BJU Int. 2008 Jun;101(11):1339-42. Epub 2008 Feb 18. Review. PubMed PMID: 18284408.

896: Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res. 2008 Mar;151(3):129-33. PubMed PMID: 18279811.

897: Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008 Jun;16(6):557-66. Epub 2008 Feb 15. Review. PubMed PMID: 18274784.

898: Machiels JP, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L. Acute cardiac failure after sunitinib. Ann Oncol. 2008 Mar;19(3):597-9. Epub 2008 Feb 13. PubMed PMID: 18272908.

899: Bradley DA, Dunn R, Nanus D, Stadler W, Dreicer R, Rosenberg J, Smith DC, Hussain M. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer. 2007 Dec;5(7):460-3. PubMed PMID: 18272031.

900: Heng DY, Rini BI, Garcia J, Wood L, Bukowski RM. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2007 Dec;5(7):446-51. PubMed PMID: 18272027.

901: Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. Epub 2008 Feb 12. PubMed PMID: 18270341.

902: Patard JJ, Pouessel D, Bensalah K, Culine S. Targeted therapy in renal cell carcinoma. World J Urol. 2008 Apr;26(2):135-40. Epub 2008 Feb 12. PubMed PMID: 18265991.

903: Mizutani Y, Nakanishi H, Mizuno M, Yoshida J, Miki T. [Molecular targeted therapy for renal cell carcinoma]. Hinyokika Kiyo. 2008 Jan;54(1):53-6. Review. Japanese. PubMed PMID: 18260362.

904: van Bronswijk H, Dubois EA, Osanto S, Cohen AF. [New drugs; sunitinib and sorafenib]. Ned Tijdschr Geneeskd. 2007 Dec 29;151(52):2888-90. Dutch. PubMed PMID: 18257434.

905: Mulherin B, Loconte NK, Holen KD. Guillain-Barré syndrome after treatment with sunitinib malate? Oncology (Williston Park). 2008 Jan;22(1):66-7, 70-1. Review. PubMed PMID: 18251284.

906: Schrader AJ, Olbert PJ, Hegele A, Varga Z, Hofmann R. Metastatic non-clear cell renal cell carcinoma: current therapeutic options. BJU Int. 2008 Jun;101(11):1343-5. Epub 2008 Jan 30. Review. PubMed PMID: 18241246.

907: Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008 Feb 1;26(4):650-6. PubMed PMID: 18235126.

908: Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal tumor. Surg Oncol. 2008 Aug;17(2):129-38. Epub 2008 Jan 30. Review. PubMed PMID: 18234489.

909: Italiano A, Bui B. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. Bull Cancer. 2008 Jan;95(1):107-16. Review. French. PubMed PMID: 18230576.

910: Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. Review. PubMed PMID: 18230058.

911: Pérez-Gracia JL, López-Picazo JM, Olier C, Alfaro C, García-Foncillas J, Melero I, Gúrpide A. [New treatments for renal carcinoma]. An Sist Sanit Navar. 2007 Sep-Dec;30(3):393-403. Review. Spanish. PubMed PMID: 18227896.

912: Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007 Nov-Dec;27(6C):4255-7. PubMed PMID: 18214028.

913: Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol. 2008 Jan;144(1):123-5. PubMed PMID: 18209189.

914: Sanz Rubiales A, Luisa Del Valle M. Disillusionment bias in clinical trials testing new drugs. Clin Oncol (R Coll Radiol). 2008 Apr;20(3):267. Epub 2008 Jan 18. PubMed PMID: 18207717.

915: Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol. 2008 Sep;54(3):489-92. Epub 2008 Jan 11. PubMed PMID: 18206292.

916: Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, Santini D, Piazzi G, Castellucci P, Brandi G, Biasco G. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol. 2008 May;134(5):625-30. Epub 2008 Jan 17. PubMed PMID: 18202855.

917: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735. PubMed PMID: 18200333.

918: Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. Review. PubMed PMID: 18192256.

919: Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007 Dec;7(4):127-34. Epub 2008 Jan 11. Review. PubMed PMID: 18188524.

920: Khosravi Shahi P, Fernández Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest. 2008 Feb;26(1):104-8. Review. PubMed PMID: 18181052.

921: Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother. 2007 Dec;5(4):341-4. PubMed PMID: 18179992.

922: Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res. 2008 Jan 1;14(1):270-80. PubMed PMID: 18172279.

923: Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008 Jan 3;358(1):95-7. PubMed PMID: 18172185.

924: Dham A, Truskinovsky AM, Dudek AZ. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol. 2008 Jan;3(1):94-7. PubMed PMID: 18166847.

925: Helgason HH, Mallo HA, Droogendijk H, Haanen JG, van der Veldt AA, van den Eertwegh AJ, Boven E. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol. 2008 Jan 1;26(1):152-4. PubMed PMID: 18165649.

926: Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008 Jan 1;26(1):127-31. PubMed PMID: 18165647.

927: Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist. 2007 Dec;12(12):1404-15. Review. PubMed PMID: 18165617.

928: Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet. 2007 Dec 22;370(9605):2071-3. PubMed PMID: 18156012.

929: Shor AC, Agresta SV, D'Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control. 2008 Jan;15(1):47-54. Review. PubMed PMID: 18094660.

930: Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15;370(9604):2011-9. PubMed PMID: 18083403; PubMed Central PMCID: PMC2643085.

931: Joensuu H. Cardiac toxicity of sunitinib. Lancet. 2007 Dec 15;370(9604):1978-80. PubMed PMID: 18083385.

932: Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol. 2008 Aug;34(8):844-50. Epub 2007 Dec 21. Review. PubMed PMID: 18082353.

933: Rauh-Hain JA, Penson RT. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):934-6. Epub 2007 Dec 13. PubMed PMID: 18081793.

934: Dova L, Pentheroudakis G, Golfinopoulos V, Malamou-Mitsi V, Georgiou I, Vartholomatos G, Ntemou A, Fountzilas G, Pavlidis N. Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol. 2008 Jun;134(6):697-704. Epub 2007 Dec 7. PubMed PMID: 18064489.

935: Newton HB. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. Curr Opin Investig Drugs. 2007 Dec;8(12):1009-21. Review. PubMed PMID: 18058572.

936: Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008 May;53(5):917-30. Epub 2007 Nov 26. Review. PubMed PMID: 18054825.

937: Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 2008 Apr;53(4):845-8. Epub 2007 Nov 20. PubMed PMID: 18053636.

938: Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol. 2008 Jan;20(1):104-11. Review. PubMed PMID: 18043264.

939: Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 2008 Jan 15;112(2):250-9. PubMed PMID: 18041064.

940: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PubMed PMID: 18040531.

941: Grávalos C, Cassinello J, Fernández-Rañada I, Holgado E. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2007 Nov;6(10):691-9. Review. PubMed PMID: 18039422.

942: Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557-86. Review. PubMed PMID: 18039140.

943: Mansueto G, Longo F. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors.]. Tumori. 2007 Sep-Oct;93(5):Suppl 1-16. Italian. PubMed PMID: 18038894.

944: Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol. 2007 Dec;14(12):1095-7; discussion 1097. PubMed PMID: 18036049.

945: Pouessel D, Culine S, Verhoest G, Patard JJ. [Renal cell carcinoma and antiangiogenic therapies]. Presse Med. 2008 Apr;37(4 Pt 2):628-33. Epub 2007 Nov 26. Review. French. PubMed PMID: 18035517.

946: Scagliotti GV. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. Ann Oncol. 2007 Sep;18 Suppl 10:x32-41. PubMed PMID: 17761722.

947: Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol. 2007 Sep;18 Suppl 10:x3-10. Review. PubMed PMID: 17761721.

948: Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007 Sep;18 Suppl 10:x25-31. Review. PubMed PMID: 17761720.

949: Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol. 2007 Sep;18 Suppl 10:x20-4. Review. PubMed PMID: 17761719.

950: DePrimo SE, Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol. 2007 Sep;18 Suppl 10:x11-9. Review. PubMed PMID: 17761718.

951: George D, Verweij J. Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'. Ann Oncol. 2007 Sep;18 Suppl 10:x1-2. PubMed PMID: 17761717.

952: Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008 Jan;179(1):81-6; discussion 86. Epub 2007 Nov 12. PubMed PMID: 17997441.

953: Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol. 2007 Nov;18(11):1906-7. PubMed PMID: 17993633.

954: Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev. 2008 Feb;34(1):37-48. Epub 2007 Nov 5. Review. PubMed PMID: 17983706.

955: Nishioka C, Ikezoe T, Yang J, Takeshita A, Taniguchi A, Komatsu N, Togitani K, Koeffler HP, Yokoyama A. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res. 2008 Jun;32(6):865-72. Epub 2007 Nov 5. PubMed PMID: 17983653.

956: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):467-509. PubMed PMID: 17982511.

957: Samlowski WE, Vogelzang NJ. Emerging drugs for the treatment of metastatic renal cancer. Expert Opin Emerg Drugs. 2007 Nov;12(4):605-18. Review. PubMed PMID: 17979602.

958: Pouessel D, Culine S. [Angiogenesis targeting in renal carcinomas]. Bull Cancer. 2007;94(7 Suppl):F223-6. Review. French. PubMed PMID: 17965000.

959: Meric JB. [Angiogenesis targeting in gastro-intestinal cancers]. Bull Cancer. 2007;94(7 Suppl):F207-15. Review. French. PubMed PMID: 17964998.

960: Erman M. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras. J BUON. 2007 Sep;12 Suppl 1:S83-94. Review. PubMed PMID: 17935283.

961: Radulovic S, Bjelogrlic SK. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON. 2007 Sep;12 Suppl 1:S151-62. Review. PubMed PMID: 17935273.

962: Irani J. [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]. Prog Urol. 2007 Sep;17(5):996. French. PubMed PMID: 17969805.

963: Thomas X. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. Bull Cancer. 2007 Oct 1;94(10):871-80. Review. French. PubMed PMID: 17964981.

964: Shirai K, O'Brien PE. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol. 2007 Jun;8(3):239-51. Review. PubMed PMID: 17962911.

965: Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008 Feb;19(2):265-8. Epub 2007 Oct 24. PubMed PMID: 17962201.

966: Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract Oncol. 2007 Dec;4(12):674. Epub 2007 Oct 23. PubMed PMID: 17955044.

967: Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct 20;25(30):4793-9. Erratum in: J Clin Oncol. 2008 Jan 20;26(3):514. PubMed PMID: 17947727.

968: Strijbos MH, Kraan J, Sleijfer S, Gratama JW. Potential biomarkers in metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Oct 15;13(20):6244. PubMed PMID: 17947493.

969: Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):261-6. Epub 2007 Sep 7. Review. PubMed PMID: 17945482.

970: Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17069-74. Epub 2007 Oct 17. PubMed PMID: 17942672; PubMed Central PMCID: PMC2040401.

971: Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, Carmeliet P, Jiménez W, Morales-Ruiz M. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007 Dec;46(6):1919-26. PubMed PMID: 17935226.

972: Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays. 2007 Nov;29(11):1159-68. Review. PubMed PMID: 17935210.

973: Defuentes G, Bladé JS, Berets O. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007 Oct 11;357(15):1556-7; author reply 1557-8. PubMed PMID: 17928609.

974: Rini BI. Sunitinib. Expert Opin Pharmacother. 2007 Oct;8(14):2359-69. Review. PubMed PMID: 17927489.

975: Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park). 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190. Review. PubMed PMID: 17926797.

976: Sankhala KK, Papadopoulos KP. Future options for imatinib mesilate-resistant tumors. Expert Opin Investig Drugs. 2007 Oct;16(10):1549-60. Review. PubMed PMID: 17922620.

977: Hutson TE, Figlin RA. Renal cell cancer. Cancer J. 2007 Sep-Oct;13(5):282-6. Review. PubMed PMID: 17921725.

978: Billemont B, Izzedine H, Rixe O. Macrocytosis due to treatment with sunitinib. N Engl J Med. 2007 Sep 27;357(13):1351-2; author reply 1352. PubMed PMID: 17898111.

979: Izzedine H, Billemont B, Thibault F, Rixe O. New challenges in kidney cancer therapy: sunitinib. Ann Oncol. 2007 Jul;18 Suppl 9:ix83-6. Review. PubMed PMID: 17631600.

980: Grimaldi AM, Guida T, D'Attino R, Perrotta E, Otero M, Masala A, Cartenì G. Sunitinib: bridging present and future cancer treatment. Ann Oncol. 2007 Jun;18 Suppl 6:vi31-4. Review. PubMed PMID: 17591828.

981: Longo R, D'Andrea MR, Sarmiento R, Salerno F, Gasparini G. Integrated therapy of kidney cancer. Ann Oncol. 2007 Jun;18 Suppl 6:vi141-8. Review. PubMed PMID: 17591809.

982: Badalamenti G, Rodolico V, Fulfaro F, Cascio S, Cipolla C, Cicero G, Incorvaia L, Sanfilippo M, Intrivici C, Sandonato L, Pantuso G, Latteri MA, Gebbia N, Russo A. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol. 2007 Jun;18 Suppl 6:vi136-40. Review. PubMed PMID: 17591808.

983: Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie. 2007 Oct;30(10):519-24. Epub 2007 Sep 21. Review. PubMed PMID: 17890892.

984: van der Veldt AA, van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol. 2007 Oct;18(10):1747-50. PubMed PMID: 17890217.

985: Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007 Oct;18(10):1745-7. PubMed PMID: 17890216.

986: Kancha RK, Grundler R, Peschel C, Duyster J. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol. 2007 Oct;35(10):1522-6. PubMed PMID: 17889720.

987: Khurdayan VK. Take-home message: are we "off target"? Drug News Perspect. 2007 Jun;20(5):345-51. PubMed PMID: 17878963.

988: vom Dorp F, Krege S, Rübben H. [Inductive systemic therapy of urological tumors with curative intent]. Urologe A. 2007 Oct;46(10):1400-3. German. PubMed PMID: 17874061.

989: Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007 Nov;178(5):1883-7. Epub 2007 Sep 17. PubMed PMID: 17868732.

990: Maisey N. Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer. Cancer Invest. 2007 Sep 11:1-5. [Epub ahead of print] PubMed PMID: 17852116.

991: Bambust I, Van Aelst F, Joosens E, Schallier D, Rezaei Kalantari H, Paulus R, Renard V, Clausse M, Duck L, Luce S, Pierre P, Van Belle S, Rottey S. A Belgian registry of interleukin-2 administration for treatment of metastatic renal cell cancer and confrontation with literature data. Acta Clin Belg. 2007 Jul-Aug;62(4):223-9. PubMed PMID: 17849693.

992: Robert C. [Cutaneous side effects of antiangiogenic agents]. Bull Cancer. 2007 Jul;94 Spec No:S260-4. Review. French. PubMed PMID: 17846013.

993: Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O. [Angiogenesis and renal cell carcinoma]. Bull Cancer. 2007 Jul;94 Spec No:S232-40. Review. French. PubMed PMID: 17846009.

994: Ropert S, Mir O, Armand JP. [Oral drugs inhibiting the VEGF pathway]. Bull Cancer. 2007 Jul;94 Spec No:S180-90. Review. French. PubMed PMID: 17846003.

995: Haas NB, Uzzo RG. Targeted therapies for kidney cancer in urologic practice. Urol Oncol. 2007 Sep-Oct;25(5):420-32. Review. PubMed PMID: 17826664.

996: Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008 Feb;53(2):376-81. Epub 2007 Sep 4. PubMed PMID: 17825982.

997: Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 2007 Jul;29(7):1338-53. Review. PubMed PMID: 17825686.

998: Doehn C, Merseburger AS, Jocham D, Kuczyk MA. [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?]. Urologe A. 2007 Oct;46(10):1371-2, 1374, 1376-8. German. PubMed PMID: 17805507.

999: Fazio N, Dettori M, Lorizzo K. Temsirolimus for advanced renal-cell carcinoma. N Engl J Med. 2007 Sep 6;357(10):1050; author reply 1050-1. PubMed PMID: 17804854.

1000: Rosa DD, Clamp AR, Collinson F, Jayson GC. Antiangiogenic therapy for ovarian cancer. Curr Opin Oncol. 2007 Sep;19(5):497-505. Review. PubMed PMID: 17762578.

1001: Murray M, Hatcher H, Jessop F, Williams D, Carroll N, Bulusu R, Judson I. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib. Pediatr Blood Cancer. 2008 Feb;50(2):386-8. PubMed PMID: 17729245.

1002: Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib. Prescrire Int. 2007 Aug;16(90):141-3. PubMed PMID: 17724834.

1003: Sunitinib: new drug. For some gastrointestinal stromal tumours. Prescrire Int. 2007 Aug;16(90):138-41. PubMed PMID: 17724833.

1004: Ding J, Feng Y, Wang HY. From cell signaling to cancer therapy. Acta Pharmacol Sin. 2007 Sep;28(9):1494-8. Review. PubMed PMID: 17723182.

1005: Sheen YS, Huang CL, Chu CY. Eccrine squamous syringometaplasia associated with sunitinib therapy. J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1136-7. PubMed PMID: 17714156.

1006: Faris JE, Moore AF, Daniels GH. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 2007 Nov;17(11):1147-9. PubMed PMID: 17714037.

1007: Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30. Review. Erratum in: J Natl Compr Canc Netw. 2007 Aug;5(7):xxx. PubMed PMID: 17624289.

1008: Buckstein R, Meyer RM, Seymour L, Biagi J, Mackay H, Laurie S, Eisenhauer E. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol. 2007 Aug;14(4):154-61. PubMed PMID: 17710208; PubMed Central PMCID: PMC1948864.

1009: Cohen R, Bihan H, Uzzan B, des Guetz G, Krivitzky A. [Sunitinib and hypothyroidism]. Ann Endocrinol (Paris). 2007 Oct;68(5):332-6. Epub 2007 Aug 20. Review. French. PubMed PMID: 17707761.

1010: Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. Breast. 2007 Dec;16 Suppl 2:S17-9. Epub 2007 Aug 17. Review. PubMed PMID: 17707641.

1011: Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch. 2007 Oct;451(4):743-9. Epub 2007 Aug 14. Review. PubMed PMID: 17701051.

1012: Chorianopoulos E, Jäger D, Katus HA, Frey N. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib. Clin Res Cardiol. 2007 Nov;96(11):829-30. Epub 2007 Aug 21. PubMed PMID: 17694380.

1013: Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem. 2007;7(14):1379-93. Review. PubMed PMID: 17692027.

1014: Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007 Sep;6(9):734-45. Review. PubMed PMID: 17690708.

1015: Nishida T. [Imatinib . Sunitinib]. Gan To Kagaku Ryoho. 2007 Aug;34(8):1196-200. Japanese. PubMed PMID: 17687201.

1016: Martín G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007 Aug 10;25(23):3559. PubMed PMID: 17687168.

1017: Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. 2007 Aug 10;25(23):3544-6. PubMed PMID: 17687160.

1018: Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007 Jul;18(7):1282-3. PubMed PMID: 17675397.

1019: Raccah E, Merimsky O, Kuten A, Apter S, Catane R. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up]. Harefuah. 2007 May;146(5):329-34, 408. Hebrew. PubMed PMID: 17674545.

1020: Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4623-7. Review. PubMed PMID: 17671153.

1021: Kibble A, Shumoogam J. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice. IDrugs. 2007 Aug;10(8):509-12. PubMed PMID: 17665319.

1022: Bodrogi I. [Effect of angiogenesis inhibitors on renal cell carcinoma]. Magy Onkol. 2007;51(2):145-53. Epub 2007 Jul 29. Review. Hungarian. PubMed PMID: 17660871.

1023: Larkin JM, Chowdhury S, Gore ME. Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9. Review. PubMed PMID: 17657252.

1024: Neill MG, Wei AC, Jewett MA. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy. Urology. 2007 Jul;70(1):178.e9-11. PubMed PMID: 17656238.

1025: Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007 Aug;27(8):1125-44. Review. PubMed PMID: 17655513.

1026: Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma]. Aktuelle Urol. 2007 Jul;38(4):328-30. German. PubMed PMID: 17647172.

1027: Hutson TE. Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent). 2007 Jul;20(3):244-8. PubMed PMID: 17637878; PubMed Central PMCID: PMC1906573.

1028: Thibault F, Billemont B, Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neurooncol. 2008 Jan;86(2):243-4. Epub 2007 Jul 19. PubMed PMID: 17634858.

1029: Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007 Feb;8(1):15-27. Review. PubMed PMID: 17634832.

1030: Froehner M, Hakenberg OW, Wirth MP. Molecular therapy in urologic oncology. Urol Int. 2007;79(1):1-7. Review. PubMed PMID: 17627159.

1031: de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol. 2007 Oct;9(4):412-23. Epub 2007 Jul 10. PubMed PMID: 17622648; PubMed Central PMCID: PMC1994098.

1032: Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. J Oncol Pharm Pract. 2007 Mar;13(1):5-15. Review. PubMed PMID: 17621562.

1033: Porta C, Paglino C, Imarisio I, Bonomi L. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. ScientificWorldJournal. 2007 Apr 9;7:837-49. Review. PubMed PMID: 17619768.

1034: Unnithan J, Rini BI. The role of targeted therapy in metastatic renal cell carcinoma. ScientificWorldJournal. 2007 Mar 2;7:800-7. Review. PubMed PMID: 17619763.

1035: Siehl J, Thiel E. C-kit, GIST, and imatinib. Recent Results Cancer Res. 2007;176:145-51. Review. PubMed PMID: 17607922.

1036: Atkins MB. The effect of recent drug approvals on translational research and drug development. Clin Adv Hematol Oncol. 2007 Apr;5(4):285-7. Review. PubMed PMID: 17607287.

1037: Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res. 2007 Jul 1;13(13):3765-70. Review. PubMed PMID: 17606705.

1038: Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007 Jul 2;5:32. PubMed PMID: 17605814; PubMed Central PMCID: PMC1939830.

1039: Di Lorenzo L. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain? J Clin Oncol. 2007 Jul 1;25(19):2858-9; author reply 2859-61. PubMed PMID: 17602094.

1040: Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist. 2007 Jun;12(6):719-26. PubMed PMID: 17602061.

1041: Maki RG. Gastrointestinal Stromal Tumors (GIST) and Their Management. Gastrointest Cancer Res. 2007;1(4 Suppl 2):S81-4. PubMed PMID: 19360154; PubMed Central PMCID: PMC2666831.

1042: Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007 Sep;92(9):3531-4. Epub 2007 Jun 26. PubMed PMID: 17595247.

1043: Stadler WM, Szmulewitz RZ. Sunitinib--a new standard of care for metastatic renal cell carcinoma. Nat Clin Pract Oncol. 2007 Aug;4(8):458-9. Epub 2007 Jun 26. PubMed PMID: 17593923.

1044: Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol. 2008 Jan;134(1):51-7. Epub 2007 Jun 26. PubMed PMID: 17593391.

1045: George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep. 2007 Jul;9(4):323-7. Review. PubMed PMID: 17588358.

1046: Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007 Jun;18(6):1117. PubMed PMID: 17586751.

1047: Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007 Aug 1;110(3):543-50. PubMed PMID: 17577222.

1048: Di Lorenzo G. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10. Eur Urol. 2007 Sep;52(3):926-8; author reply 928. Epub 2007 Jun 12. PubMed PMID: 17574728.

1049: MacIntyre J. Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors. Clin J Oncol Nurs. 2007 Apr;11(2):237-41. Review. PubMed PMID: 17573273.

1050: Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. Epub 2007 Jun 12. PubMed PMID: 17565156.

1051: Garfield DH, Hercbergs A, Davis PJ. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007 Jun 20;99(12):975-6; author reply 976-7. Epub 2007 Jun 12. PubMed PMID: 17565154.

1052: Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet. 2007 Jun 9;369(9577):1923-4. PubMed PMID: 17560435.

1053: van der Veldt AA, van den Eertwegh AJ, Boven E. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer]. Ned Tijdschr Geneeskd. 2007 May 19;151(20):1142-7. Dutch. PubMed PMID: 17557672.

1054: Galsky MD, Vogelzang NJ. Outcomes and prognosis in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2007 Jun;7(6):839-45. Review. PubMed PMID: 17555394.

1055: Kalender ME, Sevinc A, Tutar E, Sirikci A, Camci C. Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report. World J Gastroenterol. 2007 May 14;13(18):2629-32. PubMed PMID: 17552016.

1056: Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs. 2007;67(9):1257-64. Review. PubMed PMID: 17547470.

1057: Joensuu H. Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol. 2007 Jul;19(4):353-8. Review. PubMed PMID: 17545799.

1058: Gillessen S, Graf L, Korte W, Cerny T. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med. 2007 May 31;356(22):2330-1. PubMed PMID: 17538098.

1059: Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol. 2007;39(7-8):1349-57. Epub 2007 Apr 22. Review. PubMed PMID: 17537667; PubMed Central PMCID: PMC2752727.

1060: Sendi P, Puric E, Schönenberger A, Bargetzi M. [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. Praxis (Bern 1994). 2007 May 2;96(18):729-32. German. PubMed PMID: 17520841.

1061: Sartore-Bianchi A, Ricotta R, Cerea G, Maugeri MR, Siena S. Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S77-87. Review. PubMed PMID: 17520585.

1062: Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007 Jun 18;96(12):1788-95. Epub 2007 May 22. Review. PubMed PMID: 17519900; PubMed Central PMCID: PMC2359962.

1063: Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007 May 19;369(9574):1731-41. Review. Erratum in: Lancet. 2007 Aug 4;370(9585):388. PubMed PMID: 17512858.

1064: Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008 Mar;61(3):515-24. Epub 2007 May 16. PubMed PMID: 17505827.

1065: Verhagen PC. Re: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. Eur Urol. 2007 May;51(5):1444. PubMed PMID: 17494121.

1066: Blay JY. [Anti-angiogenetic agents for solid tumors]. Rev Med Interne. 2007 Jun;28 Suppl 1:S7-8. Epub 2007 Apr 20. French. PubMed PMID: 17482319.

1067: Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007 May 1;13(9):2643-50. PubMed PMID: 17473195.

1068: Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist. 2007 Apr;12(4):465-77. Review. PubMed PMID: 17470689.

1069: Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007 Apr;17(4):351-5. PubMed PMID: 17465866.

1070: de Lima Lopes G Jr, Rocha Lima CM. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib. Pharmacotherapy. 2007 May;27(5):775-7. PubMed PMID: 17461715.

1071: Mulder SF, van Spronsen DJ, De Mulder PH. Do the results of the new trials change the standard treatment of metastatic renal cell cancer? Onkologie. 2007 May;30(5):260-4. Epub 2007 Apr 25. PubMed PMID: 17460422.

1072: Eichhorn ME, Kleespies A, Angele MK, Jauch KW, Bruns CJ. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg. 2007 May;392(3):371-9. Epub 2007 Feb 16. Review. PubMed PMID: 17458577.

1073: Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007 May;7(5):332-44. Review. PubMed PMID: 17457301.

1074: Ardizzoni A, Tiseo M. Combination of target agents: challenges and opportunities. J Thorac Oncol. 2007 May;2(5 Suppl):S4-6. Review. PubMed PMID: 17457232.

1075: Vira MA, Novakovic KR, Pinto PA, Linehan WM. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. BJU Int. 2007 May;99(5 Pt B):1223-9. Review. PubMed PMID: 17441915.

1076: Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. PubMed PMID: 17440629.

1077: Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol. 2007 May;38(5):679-87. Review. PubMed PMID: 17437861.

1078: Kuczyk M, Kruck S, Merseburger AS. [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot]. Urologe A. 2007 May;46(5):504-8, 510. Review. German. PubMed PMID: 17437075.

1079: Maki RG. Recent advances in therapy for gastrointestinal stromal tumors. Curr Oncol Rep. 2007 May;9(3):165-9. Review. PubMed PMID: 17430686.

1080: Wolter P, Dumez H, Schöffski P. Sunitinib and hypothyroidism. N Engl J Med. 2007 Apr 12;356(15):1580; author reply 1580-1. PubMed PMID: 17429091.

1081: Debiec-Rychter M. Sunitinib--a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor. Nat Clin Pract Oncol. 2007 Jun;4(6):342-3. Epub 2007 Apr 10. PubMed PMID: 17426720.

1082: Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97:247-74. Review. PubMed PMID: 17419949.

1083: von Mehren M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S30-4. Review. PubMed PMID: 17419150.

1084: Bartsch R, Wenzel C, Zielinski CC, Steger GG. HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs. 2007;21(2):69-77. Review. PubMed PMID: 17402790.

1085: Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin. 2007 Mar-Apr;57(2):112-25. Review. PubMed PMID: 17392388.

1086: Beekman KW, Bradley D, Hussain M. New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin Oncol. 2007 Apr;34(2):154-64. Review. PubMed PMID: 17382799.

1087: Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):163-72. Review. PubMed PMID: 17382271.

1088: Silay MS, Miroglu C. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. Med Hypotheses. 2007;69(4):892-5. Epub 2007 Mar 26. PubMed PMID: 17368754.

1089: Michaelson MD. ASCO 2006 highlights: targeted therapy for renal cell carcinoma. Cancer Treat Rev. 2007 Jun;33(4):381-90. Epub 2007 Mar 23. PubMed PMID: 17367939.

1090: Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. PubMed PMID: 17367763.

1091: Escudier B. [Metastatic renal cell carcinoma and its treatments]. Ann Urol (Paris). 2006 Nov;40 Suppl 3:S82-5. Review. French. PubMed PMID: 17366861.

1092: Cassier PA, Dufresne A, Fayette J, Alberti L, Ranchere D, Ray-Coquard I, Blay JY. Emerging drugs for the treatment of soft tissue sarcomas. Expert Opin Emerg Drugs. 2007 Mar;12(1):139-53. Review. PubMed PMID: 17355219.

1093: Aapro MS. [Medical oncology]. Rev Med Suisse. 2007 Jan 10;3(93):49-52, 54-5. Review. French. PubMed PMID: 17354661.

1094: Longo R, Torino F, Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des. 2007;13(5):497-517. Review. PubMed PMID: 17348846.

1095: Figlin RA. Newly approved therapies for RCC and their effect on the standard of care. Clin Adv Hematol Oncol. 2007 Jan;5(1):35-6, 66. PubMed PMID: 17339824.

1096: Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007 Mar 1;13(5):1367-73. Review. PubMed PMID: 17332278.

1097: Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007 Mar 1;25(7):884-96. Review. PubMed PMID: 17327610.

1098: Two new drugs for renal cell carcinoma. Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20. PubMed PMID: 17325624.

1099: Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res. 2007 Mar;149(3):103-6. PubMed PMID: 17320795.

1100: Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007 Feb 15;13(4):1098-106. Review. PubMed PMID: 17317817.

1101: Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200. PubMed PMID: 17296815.

1102: Bukowski RM. Sunitinib in advanced renal cell carcinoma: new treatment option? Curr Oncol Rep. 2007 Mar;9(2):85-6. PubMed PMID: 17288871.

1103: Senior K. Fatigue with sunitinib-induced hypothyroidism. Lancet Oncol. 2007 Feb;8(2):101. PubMed PMID: 17288042.

1104: Hussar DA. New drugs 07, part I. Nursing. 2007 Feb;37(2):51-8; quiz 59-60. PubMed PMID: 17273084.

1105: Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102. Review. PubMed PMID: 17272980.

1106: Raut CP, Morgan JA, Ashley SW. Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Curr Opin Gastroenterol. 2007 Mar;23(2):149-58. Review. PubMed PMID: 17268243.

1107: Feldman DR, Motzer RJ. Novel targets and therapies for metastatic renal cell carcinoma. Oncology (Williston Park). 2006 Dec;20(14):1745-53; discussion 1756. Review. PubMed PMID: 17263126.

1108: Wong BY, Vogelzang NJ. Do patients with metastatic renal cell carcinoma benefit from sunitinib? Nat Clin Pract Oncol. 2007 Feb;4(2):72-3. PubMed PMID: 17259925.

1109: Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s. Review. PubMed PMID: 17255307.

1110: George DJ. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):753s-757s. Review. PubMed PMID: 17255305.

1111: Schiavon G, Santini D, Vincenzi B, Tonini G. European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006. Expert Opin Biol Ther. 2007 Feb;7(2):269-78. PubMed PMID: 17250464.

1112: Sonpavde G, Hutson TE. Recent advances in the therapy of renal cancer. Expert Opin Biol Ther. 2007 Feb;7(2):233-42. Review. PubMed PMID: 17250461.

1113: Pantuck AJ, Zomorodian N, Belldegrun AS. Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Curr Urol Rep. 2007 Jan;8(1):3-4. PubMed PMID: 17239310.

1114: Herbst RS. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 Dec;8 Suppl 1:S23-30. Review. PubMed PMID: 17239287.

1115: Hutson TE, Sonpavde G, Galsky MD. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S31-9. Review. PubMed PMID: 17239282.

1116: Speca J, Yenser S, Creel P, George D. Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S24-30. Review. PubMed PMID: 17239281.

1117: Dreicer R. Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S19-23. Review. PubMed PMID: 17239280.

1118: Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer. 2006 Dec;5(3):232-4. PubMed PMID: 17239278.

1119: Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007 Jan;12(1):107-13. PubMed PMID: 17227905.

1120: Brugarolas J. Renal-cell carcinoma--molecular pathways and therapies. N Engl J Med. 2007 Jan 11;356(2):185-7. PubMed PMID: 17215538.

1121: Drazen JM, Zarin DA. Salvation by registration. N Engl J Med. 2007 Jan 11;356(2):184-5. PubMed PMID: 17215537.

1122: Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. PubMed PMID: 17215529.

1123: Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev. 2007 Feb;17(1):3-7. Epub 2007 Jan 8. Review. PubMed PMID: 17208434.

1124: Collins S, McKiernan J, Landman J. Update on the epidemiology and biology of renal cortical neoplasms. J Endourol. 2006 Dec;20(12):975-85. Review. PubMed PMID: 17206887.

1125: Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007 Jan 3;99(1):81-3. PubMed PMID: 17202116.

1126: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Nov;28(9):657-78. PubMed PMID: 17200730.

1127: Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006 Dec 15;12(24):7215-20. Review. PubMed PMID: 17189392.

1128: Pouessel D, Culine S. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Expert Rev Anticancer Ther. 2006 Dec;6(12):1761-7. Review. PubMed PMID: 17181490.

1129: Rini BI. Molecularly targeted therapy in renal cell carcinoma: where do we go from here? Expert Rev Anticancer Ther. 2006 Dec;6(12):1753-60. Review. PubMed PMID: 17181489.

1130: Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol. 2006 Dec 20;24(36):5786-8. PubMed PMID: 17179114.

1131: Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006 Dec 10;24(35):5601-8. Review. PubMed PMID: 17158546.

1132: Good news for metastatic renal cell cancer. Health News. 2006 Sep;12(9):15. PubMed PMID: 17146857.

1133: Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. Nat Clin Pract Oncol. 2006 Dec;3(12):682-92. Review. PubMed PMID: 17139319.

1134: Sledge GW Jr, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct;4(10 Suppl 21):1-10; quiz 11-2. Review. PubMed PMID: 17139244.

1135: Deeks ED, Keating GM. Sunitinib. Drugs. 2006;66(17):2255-66; discussion 2267-8. Review. PubMed PMID: 17137406.

1136: Izzedine H, Buhaescu I, Rixe O, Deray G. Sunitinib malate. Cancer Chemother Pharmacol. 2007 Aug;60(3):357-64. Epub 2006 Nov 30. PubMed PMID: 17136543.

1137: Wetherbee SL. New weapons to snuff out kidney cancer. Nursing. 2006 Dec;36(12 Pt.1):58-63; quiz 64. Review. PubMed PMID: 17135925.

1138: Trinh QD, Cardinal E, Gallina A, Perrotte P, Saad F, Karakiewicz PI. Sunitinib relieves renal cell carcinoma spinal cord compression. Eur Urol. 2007 Jun;51(6):1741-3. Epub 2006 Nov 3. PubMed PMID: 17126991.

1139: Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol. 2007 Feb;14(2):942-53. Epub 2006 Nov 14. Review. PubMed PMID: 17103252.

1140: Blanke C. Current and future management of GIST. Clin Adv Hematol Oncol. 2006 Aug;4(8):582-3. PubMed PMID: 17099615.

1141: Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int. 2007 Feb;99(2):274-80. Epub 2006 Dec 1. Review. PubMed PMID: 17092282.

1142: Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006 Nov 7;145(9):660-4. PubMed PMID: 17088579.

1143: Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer. Ann Intern Med. 2006 Nov 7;145(9):I44. PubMed PMID: 17088575.

1144: Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, Bacik J, Motzer RJ. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006 Dec 1;107(11):2617-21. PubMed PMID: 17083126.

1145: Mellado B, Gascón P. Molecular biology of renal cell carcinoma. Clin Transl Oncol. 2006 Oct;8(10):706-10. Review. PubMed PMID: 17074668.

1146: Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs. 2006 Nov;11(4):635-50. Review. PubMed PMID: 17064223.

1147: Seandel M, Shia J, Linkov I, Maki RG, Antonescu CR, Dupont J. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6203-4. PubMed PMID: 17062698.

1148: Vollmer H. [Sunitinib for gastrointestinal stromal cell tumors and advanced renal cell carcinoma]. Med Monatsschr Pharm. 2006 Oct;29(10):386-7. German. PubMed PMID: 17058904.

1149: Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer. 2006 Nov 15;107(10):2375-83. PubMed PMID: 17048248.

1150: Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. PubMed PMID: 17046465.

1151: Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet. 2006 Oct 14;368(9544):1303-4. PubMed PMID: 17046443.

1152: Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. 2006 Oct;33(5):576-82. Review. PubMed PMID: 17045086.

1153: Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther. 2006 Oct;5(10):2522-30. PubMed PMID: 17041096.

1154: Hussar DA. New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate. J Am Pharm Assoc (2003). 2006 Sep-Oct;46(5):650-5. PubMed PMID: 17036654.

1155: Schnadig ID, Blanke CD. Gastrointestinal stromal tumors: imatinib and beyond. Curr Treat Options Oncol. 2006 Nov;7(6):427-37. Review. PubMed PMID: 17032555.

1156: Yap TA, Eisen TG. Adjuvant therapy of renal cell carcinoma. Clin Genitourin Cancer. 2006 Sep;5(2):120-30. Review. PubMed PMID: 17026800.

1157: Staehler M, Haseke N, Schöppler G, Stadler T, Heinemann G, Stief CG. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]. Urologe A. 2006 Oct;45(10):1333-42; quiz 1343. Review. German. PubMed PMID: 17021905.

1158: New hope for RCC patients. Eur J Cancer. 2006 Aug;42(12):1693. PubMed PMID: 16998955.

1159: Yang Y, Ikezoe T, Nishioka C, Taguchi T, Zhu WG, Koeffler HP, Taguchi H. ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. Cancer Sci. 2006 Dec;97(12):1404-9. Epub 2006 Sep 21. PubMed PMID: 16995874.

1160: Desch CE. We have a new treatment, but you can't afford it. J Natl Compr Canc Netw. 2006 Sep;4(8):720-3. PubMed PMID: 16995283.

1161: Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006 Nov;20(11):2008-14. Epub 2006 Sep 14. PubMed PMID: 16990784.

1162: Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006 Sep;12(7):570-7. PubMed PMID: 16981802.

1163: Stadler W. New therapeutic options for renal cell carcinoma. Clin Adv Hematol Oncol. 2006 Jun;4(6):429-30. PubMed PMID: 16981664.

1164: Ronnen EA, Kondagunta GV, Ginsberg MS, Russo P, Motzer RJ. Long-term response with sunitinib for metastatic renal cell carcinoma. Urology. 2006 Sep;68(3):672.e19-20. Epub 2006 Sep 18. PubMed PMID: 16979716.

1165: van Spronsen DJ, De Mulder PH. Targeted approaches for treating advanced clear cell renal carcinoma. Onkologie. 2006 Sep;29(8-9):394-402. Epub 2006 Sep 6. Review. PubMed PMID: 16974118.

1166: Bankhead C. Three new drugs available to fight kidney cancer. J Natl Cancer Inst. 2006 Sep 6;98(17):1181-2. PubMed PMID: 16954469.

1167: Cox MC, Dan TD, Swain SM. Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs. 2006 Sep;11(3):489-501. Review. PubMed PMID: 16939387.

1168: King CR. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses. ONS News. 2006;21(8 Suppl):57-8. Review. PubMed PMID: 16925154.

1169: Biedrzycki BA. Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes. ONS News. 2006;21(8 Suppl):21-2. PubMed PMID: 16925136.

1170: Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, Taguchi T, Koeffler HP, Taguchi H. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci. 2006 Sep;97(9):945-51. PubMed PMID: 16916320.

1171: Takahashi H, Obata R, Tamaki Y. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. J Ocul Pharmacol Ther. 2006 Aug;22(4):213-8. PubMed PMID: 16910860.

1172: New targeted therapy for rare stomach, kidney cancers. FDA Consum. 2006 May-Jun;40(3):5. PubMed PMID: 16906656.

1173: Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol. 2006 Sep;16(5):337-41. Review. PubMed PMID: 16905978.

1174: Lopez M, Comandone A, Adamo V, Apice G, Bearzi I, Bracci R, Carlini M, Carpano S, Condorelli S, Covello R, Cucchiara G, Di Filippo F, Doglietto GB, Ficorella C, Garofalo A, Gebbia N, Giuliani F, Massidda B, Messerini L, Palmirotta R, Tonelli F, Vidiri A. [Clinical guidelines for the management of gastrointestinal stromal tumors]. Clin Ter. 2006 May-Jun;157(3):283-99. Italian. PubMed PMID: 16900856.

1175: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jul-Aug;28(6):379-412. PubMed PMID: 16894408.

1176: Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82. PubMed PMID: 16891463.

1177: Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006 Jul-Aug;11(7):753-64. Review. PubMed PMID: 16880234.

1178: Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26. Epub 2006 Jul 24. Review. PubMed PMID: 16860997.

1179: Shaheen PE, Rini BI, Bukowski RM. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer. 2006 Jun;5(1):78-81. PubMed PMID: 16859583.

1180: Reddy K. Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2006 Jun;5(1):23-5. Review. PubMed PMID: 16859575.

1181: Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006 Aug;244(2):176-84. Review. PubMed PMID: 16858179; PubMed Central PMCID: PMC1602162.

1182: Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol. 2006 Jun;11(3):209-13. Review. PubMed PMID: 16850127.

1183: Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6. Epub 2006 Jul 18. PubMed PMID: 16849418.

1184: Cabebe E, Wakelee H. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc). 2006 Jun;42(6):387-98. Review. PubMed PMID: 16845442.

1185: Hampton T. Trials probe new agents for kidney cancer. JAMA. 2006 Jul 12;296(2):155-7. Erratum in: JAMA. 2007 Apr 25;297(16):1774. PubMed PMID: 16835411.

1186: Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006 Oct;98(4):756-62. Epub 2006 Jul 7. PubMed PMID: 16827904.

1187: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Apr;28(3):185-206. PubMed PMID: 16810345.

1188: Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol. 2006 Jul;18(7):785-7. Review. PubMed PMID: 16772838.

1189: Tokuda Y, Saito Y, Suzuki Y. [Molecular-targeted agents in breast cancer]. Gan To Kagaku Ryoho. 2006 Jun;33(6):747-53. Review. Japanese. PubMed PMID: 16770092.

1190: Pasche B. A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA. 2006 Jun 7;295(21):2537-8. PubMed PMID: 16757727.

1191: Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 7;295(21):2516-24. PubMed PMID: 16757724.

1192: Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther. 2006 May;5(5):1280-9. PubMed PMID: 16731761.

1193: de Groot JW, Links TP, van der Graaf WT. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol. 2006 Nov;17(11):1719-20. Epub 2006 May 26. PubMed PMID: 16731538.

1194: Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20;24(15):2325-31. PubMed PMID: 16710031.

1195: Borner MM. [Molecular targets in colon cancer]. Ther Umsch. 2006 Apr;63(4):243-8. Review. German. PubMed PMID: 16689454.

1196: Katoh Y, Katoh M. Comparative integromics on VEGF family members. Int J Oncol. 2006 Jun;28(6):1585-9. PubMed PMID: 16685460.

1197: Bleumer I, de Mulder PH, Mulders PF. The role of adjuvant therapy in non-metastatic RCC. Can J Urol. 2006 Apr;13 Suppl 2:57-62. Review. PubMed PMID: 16672131.

1198: Lee D, Heymach JV. Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer. 2006 Mar;7(5):304-8. Review. PubMed PMID: 16640800.

1199: Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res. 2006 Apr 15;12(8):2622-7. PubMed PMID: 16638875.

1200: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Mar;28(2):121-42. PubMed PMID: 16636723.

1201: Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs. 2006 May;15(5):553-61. Review. PubMed PMID: 16634693.

1202: Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov. 2006 Apr;5(4):279-80. PubMed PMID: 16628834.

1203: Tiseo M, Franciosi V, Ardizzoni A. Multi-target inhibitors in non-small cell lung cancer (NSCLC). Ann Oncol. 2006 Mar;17 Suppl 2:ii55-57. Review. PubMed PMID: 16608985.

1204: Susman E. New drug increases survival in stomach cancer. Lancet Oncol. 2006 Apr;7(4):286. PubMed PMID: 16598877.

1205: Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus KJ. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs. 2006 Mar;17(3):353-8. PubMed PMID: 16520665.

1206: Rini BI. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep. 2006 Mar;8(2):85-9. Review. PubMed PMID: 16507216.

1207: Koga S, Kanetake H. [Progress in therapeutic strategy for renal cell carcinoma]. Gan To Kagaku Ryoho. 2006 Feb;33(2):171-7. Review. Japanese. PubMed PMID: 16484851.

1208: Kuefer R, Autenrieth M, Herkommer K, Blum P, Merseburger A, Hofer M, Rinnab L, Gschwend J, Ringhoffer M. [Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway]. Urologe A. 2006 Mar;45(3):328, 330-5. Review. German. PubMed PMID: 16465522.

1209: Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006 Mar 13;94(5):614-9. Review. PubMed PMID: 16465192; PubMed Central PMCID: PMC2361211.

1210: Kiyoi H. [Possibility of targeting FLT3 kinase for the treatment of leukemia]. Rinsho Ketsueki. 2005 Mar;46(3):187-97. Review. Japanese. PubMed PMID: 16447713.

1211: Gollob JA. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):167-74. Review. PubMed PMID: 16425993.

1212: Rini BI. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):175-80. Review. PubMed PMID: 16425985.

1213: Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17. Review. PubMed PMID: 16418310.

1214: Pagel MD, Baldwin SJ, Rader RK, Kotyk JJ. Assessment of anti-metastatic drug efficacy via localization and quantification of ex vivo murine bone tumor load using high-throughput MRI T1 parametric analysis. NMR Biomed. 2006 Feb;19(1):1-9. PubMed PMID: 16411252.

1215: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Dec;27(10):711-38. PubMed PMID: 16395422.

1216: Kim DW, Huamani J, Fu A, Hallahan DE. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):38-46. PubMed PMID: 16377414.

1217: Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5. PubMed PMID: 16330672.

1218: Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol. 2006 Jan 1;24(1):1-3. Epub 2005 Dec 5. PubMed PMID: 16330665.

1219: Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006 Jan 1;24(1):25-35. Epub 2005 Nov 28. PubMed PMID: 16314617.

1220: Stadler WM. New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol. 2006 Jan 1;24(1):4-5. Epub 2005 Nov 28. PubMed PMID: 16314613.

1221: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Sep;27(7):505-22. PubMed PMID: 16258596.

1222: Favaro JP, George DJ. Targeted therapy in renal cell carcinoma. Expert Opin Investig Drugs. 2005 Oct;14(10):1251-8. Review. PubMed PMID: 16185167.

1223: Cooney MM, Remick SC, Vogelzang NJ. Novel agents for the treatment of advanced kidney cancer. Clin Adv Hematol Oncol. 2004 Oct;2(10):664-70. Review. PubMed PMID: 16163253.

1224: Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S31-8. Review. PubMed PMID: 16159417.

1225: Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, Sbarbati A, Osculati F. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res. 2005 Aug 15;11(16):5827-32. PubMed PMID: 16115922.

1226: Cooney MM, Remick SC, Vogelzang NJ. Promising systemic therapy for renal cell carcinoma. Curr Treat Options Oncol. 2005 Sep;6(5):357-65. Review. PubMed PMID: 16107239.

1227: Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med. 2005 Aug 16;143(4):313-4. PubMed PMID: 16103482.

1228: Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6. Epub 2005 Jul 26. PubMed PMID: 16046538; PubMed Central PMCID: PMC1180625.

1229: Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int. 2005 Aug;96(3):286-90. Review. PubMed PMID: 16042715.

1230: Wang JQ, Miller KD, Sledge GW, Zheng QH. Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4380-4. PubMed PMID: 16019210.

1231: Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005 Jul;6(7):491-500. Review. PubMed PMID: 15992698.

1232: Branca MA. Multi-kinase inhibitors create buzz at ASCO. Nat Biotechnol. 2005 Jun;23(6):639. PubMed PMID: 15940222.

1233: Niermann KJ, Fleischer AC, Donnelly EF, Schueneman AJ, Geng L, Hallahan DE. Sonographic depiction of changes of tumor vascularity in response to various therapies. Ultrasound Q. 2005 Jun;21(2):61-7; quiz 149, 153-4. PubMed PMID: 15905816.

1234: Desai AA, Stadler WM. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar;7(2):116-22. Review. PubMed PMID: 15717945.

1235: Sakamoto KM. Su-11248 Sugen. Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39. Review. PubMed PMID: 15648955.

1236: Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis. 2004;7(3):225-33. PubMed PMID: 15609077.

1237: Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005 Feb 10;23(5):939-52. Epub 2004 Nov 22. PubMed PMID: 15557593.

1238: Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors. Clin Lung Cancer. 2004 Sep;6(2):74-6. Review. PubMed PMID: 15476593.

1239: Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005 Feb 1;105(3):986-93. Epub 2004 Sep 30. PubMed PMID: 15459012.

1240: Tuma RS. Three molecularly targeted drugs tested in kidney cancer clinical trials. J Natl Cancer Inst. 2004 Sep 1;96(17):1270-1. PubMed PMID: 15339961.

1241: Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004 Dec 15;104(13):4202-9. Epub 2004 Aug 10. PubMed PMID: 15304385.

1242: Eichhorn ME, Strieth S, Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat. 2004 Apr;7(2):125-38. Review. PubMed PMID: 15158768.

1243: Broxterman HJ, Georgopapadakou NH. New cancer therapeutics: target-specific in, cytotoxics out? Drug Resist Updat. 2004 Apr;7(2):79-87. PubMed PMID: 15158764.

1244: Sistla A, Sunga A, Phung K, Koparkar A, Shenoy N. Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials. Drug Dev Ind Pharm. 2004 Jan;30(1):19-25. PubMed PMID: 15000426.

1245: Morimoto AM, Tan N, West K, McArthur G, Toner GC, Manning WC, Smolich BD, Cherrington JM. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene. 2004 Feb 26;23(8):1618-26. PubMed PMID: 14985702.

1246: Barattè S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q. Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. PubMed PMID: 14753710.

1247: Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20(8):757-66. PubMed PMID: 14713109.

1248: O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003 Nov 15;9(15):5465-76. PubMed PMID: 14654525.

1249: Shiotsu Y. [Current screening for molecular target therapy of cancer]. Gan To Kagaku Ryoho. 2003 Nov;30(12):1863-72. Review. Japanese. PubMed PMID: 14650952.

1250: von Mehren M. New therapeutic strategies for soft tissue sarcomas. Curr Treat Options Oncol. 2003 Dec;4(6):441-51. Review. PubMed PMID: 14585225.

1251: Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003 Oct;2(10):1011-21. PubMed PMID: 14578466.

1252: Moshinsky DJ, Ruslim L, Blake RA, Tang F. A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype. J Biomol Screen. 2003 Aug;8(4):447-52. PubMed PMID: 14567797.

1253: Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther. 2003 Nov;307(2):476-80. Epub 2003 Sep 9. PubMed PMID: 12966161.

1254: Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003 Jul 15;63(14):4009-16. PubMed PMID: 12873999.

1255: Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003 May;2(5):471-8. PubMed PMID: 12748309.

1256: Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27;46(7):1116-9. PubMed PMID: 12646019.

1257: Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. PubMed PMID: 12538485.

1258: O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16. PubMed PMID: 12531805.